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Clinical Trial (CT) simulation is used by academic research centers and pharmaceutical 
companies to improve the efficiency and accuracy of drug development. Sophisticated 
commercial software for CT simulations is available for those with resources to cover fees and 
with design challenges that happen to match the software’s capabilities. Academic research 
centers usually use locally developed or shared software for study design, mainly due to cost and 
flexibility considerations. Inspired by the success and immense influence of open-source 
software development projects, we are building an open-source simulation experiment platform 
with the intention of utilizing the power of distributed study design expertise, development 
talent, and peer review of code. The code base relies on S4 classes and methods within R. 
Design, baseline characteristic model, population model, outcome model, and evaluation 
criterion are five key object types. An action queue-based approach allows for complex decision 
making at the patient or CT level. Name matching mechanism is used to check interoperability 
among the objects. Extensibility, reuse and sharing come from the class/method architecture, 
together with automatic object and documentation discovery mechanisms. 
An extensive literature review of existing design evaluation criteria did not reveal the use 
of criteria based on utility functions. In this dissertation, we propose flexible criteria for 
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evaluating Phase I trial designs by assessing through CT simulation the expected total personal 
utility, societal utility and total utility.  
To illustrate the application, we present several examples using the platform to 
investigate important questions in clinical trial designs. Specifically, we look at the logit model 
in the continual reassessment method (CRM), choices of parameterization and prior distribution 
for its model parameters, and the effect of patient heterogeneity on the performance of the 
standard “3+3” design and the CRM. 
This work creates an open-source highly flexible and extensible platform for evaluating 
CT designs via simulation, and promotes collaborative statistical software development. Its 
impact on public health will manifest itself in greatly speeding and expanding thorough and 
thoughtful design evaluations when developing clinical trials, for a community of CT designers.  
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1.0  INTRODUCTION 
1.1 STATEMENT OF PROBLEMS 
In the past few decades, clinical trial (CT) designers have proposed many designs for trials at 
different stages of drug development, ranging from preclinical to Phase IV trials. This abundance 
of designs mandates a question for the investigators and statisticians planning a trial: what design 
would be the “best” for their trial? Determining the answer must begin with careful consideration 
of the criterion by which to judge designs, which should reflect the goals of the trial.  
CT simulation is used by pharmaceutical companies and FDA to improve the efficiency 
and accuracy of drug development [1-4]. Sophisticated commercial software for trial simulations 
is available for those with resources to cover fees and with design challenges matching the 
software’s capabilities. The source code of commercial software is proprietary, so users have to 
believe the software does what it claims. Academic research centers usually use locally 
developed software mainly due to cost and flexibility considerations. Cost issues are obvious. 
For example, the recent quote price of a one-year single academic license for Pharsight trial 
simulator is $11,235. Flexibility is needed primarily to explore novel designs and novel 
evaluation criteria. This local software development focuses on answering specific research 
questions in compressed time frames, and is not routinely sharable.  
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Open source software (OSS) is computer software for which the source code and certain 
other rights normally reserved for copyright holders are provided under a software license that 
meets the Open Source Definition [5] or that is in the public domain. OSS development approach 
has helped produce reliable, high quality software quickly and inexpensively. Besides, it offers 
the potential for a more flexible technology and quicker innovation. OSS covers a myriad of uses 
- from enterprise ecommerce to academic research, for example, Linux, Apache, Firefox and R 
packages. Open source solution may disseminate the innovative ideas in CT design efficiently. 
When evaluating designs for a particular clinical trial, CT designers usually have some 
prior information from previous studies on the sampling distribution for patient characteristics 
which are relevant to the patient outcomes and/or patient-level decision-making in a clinical trial. 
There may be some knowledge or belief about the biological mechanisms by which outcomes 
arise, which may point to possible model types (e.g. logit or exponential models for the dose-
toxicity response relationship), the probability of each model type, and the distribution for the 
model parameters. The classical way to utilize such prior information is to select several 
scenarios (models with specific parameter assignments), with the hope that they sufficiently 
represent the range of possible truths, and then to evaluate designs under each of these scenarios, 
applying requirements such as a cap on the type I and type II errors. This classical approach has 
problems: a small set of scenarios may not be sufficient, and the methods for synthesizing the 
evaluation results from different scenarios are somewhat artificial. The expected utility paradigm 
of Bayesian decision theory is well suited to helping CT designers with incorporating such prior 
information, and providing a comprehensive evaluation of design operating characteristics. 
However, an extensive literature review of existing design evaluation criteria did not reveal the 
criteria based on the expected utility. 
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Patients enrolled in Phase I cancer trials vary greatly in type of cancer, numbers and types 
of previous treatment, age, sex, genetic profile and many other factors that may impact their 
tolerance to the testing treatment. Ignoring patient heterogeneity in the Phase I trials may do 
harm to patients or recommend an either suboptimal or too toxic dose for future studies. In 
practice, however, few Phase I clinical trials account for patient heterogeneity. This dissertation 
explores the effects of patient heterogeneity on CT design performance. 
The Phase I dose-finding designs using the continual reassessment method (CRM) 
present challenges and opportunities. It was first introduced by O’Quigley et al. in the year 1990 
[6], and has inspired many variations [7-14]. The CRM and its variations assume the probability 
of toxicity response increase monotonically with dose via a parametric model. They typically 
apply Bayesian methods and assign prior distributions to the parameters in the model, although 
maximum likelihood methods have been proposed [15]. Single-parameter models are usually 
used and the choice of the intercept values seems arbitrary. There has been a divergent opinion 
about the number of parameters used in the model [16-20]. Supporters for single-parameter 
models argue that they can adequately approximate the dose-toxicity response relationship by a 
single parameter in the range of true target dose and that it is not possible to reliably estimate two 
or more parameters in Phase I clinical trials where sample sizes are small. However, as Phase I 
trials grow in complexity, for example, late-onset toxicity response and combined therapy, the 
single-parameter model may not be rich enough to describe underlying outcome model 
sufficiently. A major challenge is how to frame Bayesian priors for the one- and multi- parameter 
models. We find that the use of rescaled doses, to be discussed in Section 5.1.1, obscures the 
interpretations of parameters, making specification of priors unnecessarily difficult. Using easily 
interpretable parameters would help to choose the number of free parameters in a model, and to 
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set up sensible prior distributions that genuinely reflect the investigators’ prior beliefs. Thus, 
efforts are necessary to define dose-toxicity models with more interpretable parameters in the 
CRM. 
1.2 OBJECTIVES OF THE STUDY 
The primary objective of this dissertation was to build a transparent, extendible simulation 
experiment platform and to provide standards for further development so that CT designers can 
evaluate available designs and/or share their innovations. Five specific objectives are described 
briefly as follows: 
Objective 1: Review Phase I dose-finding clinical trial designs. 
Objective 2: Review the existing Phase I design evaluation criteria and present new criteria for 
evaluating the expected total personal utility, societal utility and total utility. 
Objective 3: Build an action-queue based open-source extendible simulation experiment 
platform, and develop it into an R package. 
Objective 4: Re-parameterize the logit model in the CRM for more interpretable parameters, and 
investigate the choices of prior distribution using the platform. 
Objective 5: Quantitatively demonstrate the effect of ignoring patient heterogeneity on the CRM 
and the standard “3+3” design with respect to the expected total personal utility and societal 
utility. 
  
 5 
2.0  OVERVIEW OF PHASE I DOSE-FINDING CLINICAL TRIAL DESIGNS  
Phase I trials are typically very small, uncontrolled and sequential studies of human subjects 
designed to determine the recommended dose of an experimental drug for the subsequent Phase 
II trials. Probably because of the non-randomization and small sample size, statistical 
considerations were ignored for many years in the Phase I trial designs. Nowadays, the statistical 
input is becoming more and more important in designing Phase I trials to more accurately and 
efficiently choose a dose for the subsequent Phase II trials while minimizing the patient risks. In 
addition to the toxicity risk, the patients in Phase I cancer trials also incur the risk of receiving 
sub-therapeutic doses, which is of less concern in Phase I trials for milder diseases. The goal of 
this chapter is to provide a general introduction to the Phase I trial and its designs, and to review 
the recent development of the Phase I dose-finding cancer trial designs between 2007 and 2010. 
2.1 INTRODUCTION 
Phase I clinical trials are the first step in testing a new treatment in people. They can be first-in-
human trials, or new studies of an agent or agents previously evaluated in humans, which 
includes new agent formulations, routes of administration, combinations of agents and etc. One 
primary objective of the Phase I trials is to determine an appropriate dose for the Phase II trials. 
That dose is usually called maximum tolerated dose (MTD) with the assumption that the 
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probabilities of having toxicity and/or efficacy responses increase with the increasing dose. This 
assumption is generally valid when the testing drugs are cytotoxic agents, however, it may fail in 
some biologic agents. More general terms, for example, Phase II recommended dose (P2RD), 
recommended Phase II dose (RP2D) and optimal dose (OD), have been used in the literature. In 
this dissertation, we use the term OD to refer to the true target dose that a particular Phase I trial 
should recommend for the subsequent Phase II trial under a specific criterion given complete 
knowledge, i.e. OD is the dose that optimizes a specific criterion if we know everything; we use 
RP2D as the dose that is recommended for the subsequent Phase II trial at the end of a particular 
Phase I trial. The second primary objective of the Phase I trials is to identify the toxicities 
associated with the testing treatment, particularly the dose-limiting toxicities (DLTs). DLT is 
usually defined as adverse events sufficiently morbid that constitute a practical limitation to the 
delivery of the treatment. In general, DLTs are grade ≥ 3 non-hematological and grade 4 
hematological toxicities (the latter not including grade 3 because hematological toxicities have 
become generally easier to manage). The “Common Terminology Criteria for Adverse Events” 
(CTCAE, v3.0) are currently used to grade toxicities.  The CTCAE are available at the website 
(http://ctep.cancer.gov) of the National Cancer Institute’s Cancer Therapy Evaluation Program 
(CTEP). 
The designs for the Phase I trials fall into two categories.  Algorithm-based designs, 
which do not assume any OD, and regard RP2D as a statistic calculated directly from data; 
Model-based designs, which have OD as a parameter, and regard RP2D as an estimate of the 
OD. Compared to the algorithm-based designs, model-based designs can improve the efficiency 
if the model assumptions are satisfied. However, when the model assumptions are incorrect, 
model-based designs can lead to an inaccurate estimate of OD, and it may either overdose or 
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underdose participants in the trials unnecessarily. Therefore, robustness of a model-based design 
to the model misspecifications is important to check.  Some two-stage designs mix algorithm- 
and model- based methods, with the first-stage algorithm-based and the second model-based [5-
7]. These mixture designs intend to begin the second stage near the OD, where model-based 
methods may work better.  
Eisenhauer et al.’s review paper [21] declares three components to a Phase I trial design: 
(1) the starting dose, (2) the number of patients per dose level, and (3) the dose-escalation 
scheme. One-tenth of the mouse LD10 (the dose that was lethal to 10% of animals) has 
historically been selected to be a safe starting dose in humans, as long as that dose is not lethal or 
life-threatening to a second species (e.g. rat, dog) [22]. Increasing the starting dose could 
potentially reduce the trial length and decrease the number of patients receiving ineffective 
doses. Attempts have been tried to find a higher safe starting dose [21], notably through the use 
of interspecies scaling [23]. Decreasing the number of patients per dose level would limit the 
number of patients exposed to very low doses and might shorten the trial length if the 
recruitment of patients per dose level is rate limiting. However, it could be problematic when 
there are only few patients per dose level (e.g. a single patient per dose level) in some trials 
where the patient population is very heterogeneous or the pharmacokinetic measurements are 
required. Finally, the dose-escalation scheme has attracted considerable attention from 
statisticians. More aggressive dose-escalation in the initial portion of the trial may shorten the 
length of a trial but may cause more patients to experience serious toxicity responses. Therefore, 
risks and benefits affected by the aggressiveness of dose-escalation need careful consideration 
[24]. 
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Investigators conducting Phase I trials must adhere to the ethical norms of clinical 
research [25-31].  Participants in Phase I cancer trials are almost always patients with refractory 
disease or for whom there is no standard therapy, often at a very high risk death, who consent to 
participate in the trial only as a last resort in seeking a cure. These trials raise special ethical 
issues in the dose- escalation process because of a fundamental conflict: on the one hand, there is 
a need to avoid a large jump from a dose with no observable toxicity to a lethal dose; on the 
other hand, there is a need to go rapidly, so that large numbers of patients are not treated at 
ineffective doses. One of the attempts to resolve this conflict is to construct a utility function 
associated with the bivariate outcome (toxicity and efficacy responses) [32] and select the dose 
that maximizes the expected utility for each patient. 
A number of Phase I trial designs have been proposed in the past few decades ([6, 8, 9, 
15, 33-36], among others). Despite a number of criticisms against the standard 3+3 design, in 
practice, it is still the most frequently used probably because it is easy to understand and 
implement. More recent designs often target specialized situations, such as late-onset toxicity, 
combined agents, patient population heterogeneity and ordinal toxicity outcomes. Several 
authors have provided comprehensive reviews of the Phase I trial designs prior to the year 2007 
[21, 22, 24, 37-48]. The purpose of this chapter is to review the Phase I dose-finding cancer trial 
designs which were proposed between the year 2007 and 2010. Section 2.2.1 reviews the designs 
which consider only a single outcome (usually toxicity) and section 2.2.2 reviews designs 
considering a bivariate outcome (toxicity, efficacy). We review papers in the sense of original 
terminology and notation, which can be variable across papers. 
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2.2 RECENT DEVELOPMENT 
2.2.1 Designs for single outcome 
Most Phase I dose-finding designs dichotomize toxicity grades based on DLT, wherein the 
outcome is regarded as “toxicity” if a patient experiences DLT, and “non-toxicity” if a patient 
does not experience DLT. However, this dichotomization may discard a lot of useful information 
[41] , for example, by equating life-threatening, irreversible, or long-duration toxicities with 
others[49]. Liu et al. [50] presented a parametric sequential design based on the proportional 
odds model with ordinal toxicity response in a discrete dose space. A simple and flexible penalty 
function was used in the cumulative information matrix to construct a penalized local optimality 
criterion for finding multiple quantiles of ordinal data. Ivanova and Kim [51] proposed a unified 
approach to dose finding in the studies where the quantity of interest is a monotone function of 
the dose and the goal is to estimate the dose corresponding to a pre-specified desired value of the 
function. The function may be a certain weighted sum of rates of various toxicity grades or the 
expected value of a continuous outcome. In their design, dose-escalation depends on the 
normalized difference between the current dose and the target dose at which the outcome of 
interest is equal to the pre-specified value. Yuan et al. [49] described a simple way to incorporate 
multiple ordinal toxicity grades using quasi-Bernoulli likelihood and then couple this likelihood 
with the continual reassessment method (CRM) to dose finding. They measured the relative 
severity of different toxicity grades by equivalent toxicity (ET) score, normalized the ET scores 
against the maximum and obtained the quasi-maximum likelihood estimate (QMLE) of MTD.  
Potthoff and George [52] treated toxicity response as a continuous variable, ranging from 0 to 1. 
They defined MTD as the dose with the targeted mean toxicity. The distribution of toxicity given 
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dose was assumed to follow a beta distribution with mean modeled by a two-parameter logistic 
model. Their design chooses the dose for each patient that maximizes the weighted sum of two 
quantities, (1 - posterior toxicity estimate) and the inverse of the posterior estimated variance of 
MTD. 
Many modified or extended CRM designs have been proposed ever since the original 
CRM proposal appeared in the year 1990 [6]. A one-parameter power model, 
1{( ,..., ) : (0, )}jp p
α α α ∈ ∞  is usually used in CRM for modeling toxicity probabilities, and 
clinicians need to pre-specify the values { , 1,.., }jp j J= . The choice of { , 1,.., }jp j J= affects 
design properties. An unwillingness to pre-specify { , 1,.., }jp j J=  is one of the obstacles for 
clinicians to accept the CRM method.  To overcome this arbitrariness and further enhance the 
robustness of the CRM design, Yin and Yuan [53] suggested using multiple parallel power 
models with different pre-specifications of { , 1,.., }jp j J= and possibly different prior 
distribution of α . A Bayesian model averaging (BMA) approach is then applied to estimate the 
posterior probabilities of toxicity. CRM has been criticized for exposing too many patients to 
doses higher than the MTD if the model or prior is not correctly specified. Babb et al. [54] 
proposed the escalation with overdose control (EWOC) method to minimize the number of 
overdosed patients. However, their dose escalation is slower and more patients receive sub-
therapeutic doses compared to CRM. Chu et al. [55]  unified CRM and EWOC approaches and 
presented a hybrid design to combine the strengths from both approaches. The original CRM 
described by O’Quigley [6] used single-patient cohorts which needs fewer patients but may take 
longer time. CRM has been extended to allow for multiple-patient cohorts (usually 3 patients) to 
shorten the trial duration but may need more patients or reduce the accuracy of the MTD 
estimate [8]. Huang and Chappell [56]  introduced three-dose-cohort designs which randomly 
 11 
administer three patients in the same cohort with three different doses (low, medium and high) 
according to the quantiles of the posterior distribution of the parameter in dose-response model. 
Their simulation results demonstrated their designs combined some advantages from both single-
patient cohort CRM and three-patient cohort CRM where the patients in the same cohort receive 
the same dose.   
Time-to-Event CRM (TITE-CRM) [14] is a popular method to address the problem of the 
late-onset toxicities. Bekele et al. [57] modified TITE-CRM by providing rules for suspending 
accrual if the predicted risk of toxicity is unacceptably high. This modification improves the 
safety of the trial at the price of longer duration on average.  
When the toxicity is reversible and the carry-over effect of doses can be diminished after 
a short washout period, intra-patient dose escalation can be useful for more effectively providing 
information on inter-patient variability; it also increases the chances that patients receive 
therapeutic doses. Fan and Wang [58] proposed an “m-dose design” which treats patients having 
no toxicity response at their current doses with the next higher dose until they have received m 
doses or their current dose is the highest dose. They also extended Leung and Wang’s  method 
[59] from the single-dose to the “m-dose design” and obtained an iterative nonparametric 
estimator for the probabilities of toxicities. 
Dose-finding in the Phase I trials is usually regarded as an estimation problem. In some 
Phase I trial designs, the precision (inverse variance) of the estimated OD plays the role of utility 
function or the condition for the stopping rule. Most of the designs assume a monotonic 
increasing dose-toxicity relationship. The design properties worsen seriously if this assumption is 
not valid. Cheung [60]  explored a class of algorithm-based designs based on two-stage stepwise 
testing procedures without the monotonicity assumption.  The goal of this design is to identify 
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the MTD with high probability while keeping the probability of choosing an unsafe dose low. 
The stepwise test is defined with respect to the family of hypotheses, 0 :i iH p φ≥ versus 
1 :i iH p φ<  for 1,...,i K= , where ip is the true toxicity probability at the i th dose level and φ is 
some toxicity probability which is a little higher than the target toxicity rate but still within the 
safe range. Their defined family-wise error rate (FWER) and PCS are used to control the type I 
and type II errors of this stepwise testing procedure. Extensive simulations demonstrate their 
designs have competitive operating characteristics under a wide range of scenarios but may 
require larger than typical sample size. 
Zandvliet et al. [61] proposed a two-stage model-based design for finding the 
recommended Phase II doses for various regimens of the same drug. The first stage of their 
design is the conduct of a Phase I study for a single regimen using conventional modified 
Fibonacci-like dose escalation. Then a pharmacokinetic and pharmacodynamic population model 
is developed from the data collected in the first stage, and used for performing a simulation 
study. They use the five percentile of recommended doses obtained from the simulation study as 
the starting dose for the Phase I studies with other regimens. After the conduct of all the Phase I 
studies, the recommended doses for further studies are determined through a post-hoc analysis. 
They demonstrated via simulation that their design may help to reduce the number of patients 
treated under sub-optimal doses, and to increase the precision of dose selection for Phase II 
evaluation compared to the conventional design. 
 To shorten the study duration, Skolnik et al. [62] proposed a “rolling six” design which 
allows for accrual of two to six patients concurrently onto a dose level based on the number of 
currently enrolled evaluable patients and the number of DLTs. Simulations shows that their 
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design considerably decreases the trial duration without increasing the toxicity risk and sample 
size significantly compared to the standard 3+3 design. 
Combined therapy has long been a commonplace in cancer clinical trials due to its 
occasional dramatic successes, together with hopes of potential synergistic therapeutic effects 
and non-overlapping toxicities. The toxicity ordering in the multi-dimensional dose combination 
space is typically unknown. Thus, imposing the usual assumption of non-decreasing dose-
response relationship in the Phase I trials with combined agents requires adopting some ordering 
with little or no justification. This poses a big design challenge for biostatisticians to efficiently, 
accurately and ethically choose the appropriate dose combination for the subsequent Phase II 
trial. A popular dose-search path is to first escalate one agent while the other agents are at the 
lowest dose level, then escalate the second agent while the first agent is at the highest acceptable 
dose level and the other agents are at the lowest dose level, and keep doing until the last agent is 
tested. Even though this approach is easy to understand, it may miss the best combination of the 
agents. Fan et al. [63] presented a strategy for searching MTD (here, D represents dose 
combination) within all possible dose combinations in a two-agent combination clinical trial. 
They provided two versions of design. One is a two-stage design in which the first stage selects 
MTD candidates and the second stage identifies an MTD among them; The other, more complex, 
has a preliminary stage to find a starting dose combination, along the diagonal of the tier dose 
plane, based on the observations of toxicity responses at and below DLT. Subsequently, 
escalation can only move up one dose level of one drug at each step. Yin and Yuan published 
two papers [64, 65] in the year 2009 for combined agents dose-finding trial designs. Like CRM, 
they assumed that the toxicity rate at the j th dose level for the i th agent is in the form of ijp
α , 
where the ijp are physician-specified initial guesses for the toxicity rates and α is an unknown 
 14 
positive parameter to enhance the flexibility and to accommodate physicians’ uncertainty. Dose 
escalation or de-escalation is restricted to changing one agent by no more than one dose level. 
The Bayesian dose-finding algorithm is based on the fixed probability cut-offs for dose 
escalation and de-escalation. They proposed [64] a Bayesian adaptive design which models the 
binary toxicity outcomes through a series of 2x2 contingency tables. They jointly model the 
probabilities in the contingency table at each dose combination using the Gumbel model [66], 
where the association parameter characterizes the agent synergistic effect. They also proposed 
[65] a different Bayesian adaptive design for dose-finding trials combining more than two 
agents. The synergistic effect of combined agents is modeled using a copula-type regression. 
2.2.2 Designs for bivariate outcome 
Patients in Phase I cancer trials are very heterogeneous in the disease type and extent. However, 
most of the designs proposed or used in the real Phase I clinical trials ignore this inter-subject 
variability. Thall et al. [36] extended the Thall and Cook method [67] by accounting for patient 
covariates and dose-patient covariate interactions. They used historical data to obtain an 
informative prior on the patient covariate main effects and assumed uninformative priors for all 
dose effect parameters. Their method is very complex and computationally intensive. It will 
require a substantial effect from both statistician and physicians planning the trials. Nonetheless, 
their simulation results shows that ignoring the patient heterogeneity in the dose-finding trials 
runs a high risk of assigning inferior doses to particular patient subgroups. Further research to 
develop simpler designs accounting for patient heterogeneity is warranted. 
Ivanova et al. [68] presented an adaptive dose-finding strategy based on both toxicity and 
efficacy in a crossover study setting. In their example, efficacy and toxicity are measured by a 
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continuous variable and binary variable respectively.  They assume that the mean efficacy 
response increases with doses in the lower dose range and may possibly decrease with doses in 
the higher dose range, while toxicity rate is non-decreasing throughout the dose range. They 
define a utility function which takes into account both efficacy and toxicity responses. Their 
design concentrates on assigning more patients at and around the dose which maximizes the 
utility function.  Application of their design to a Merck study showed that their proposed design 
saves sample size compared to the traditional design (equal allocation crossover design) while 
maintaining similar power for the primary comparison with placebo. 
Dragalin et al. [69] introduced a two-stage design based on the bivariate probit dose-
response model, using optimal experimental design methodology to construct a dose allocation 
procedure balancing efficiency with the desire to maximize the number of patients receiving both 
safe and efficacious doses. The efficiency is inversely proportional to the variance of the 
estimator for the target dose. They presented some reasonable penalty functions to add to the 
optimality criterion to address concerns with respect to the ethics and cost. This two-stage design 
was shown to perform fairly well under any initial design in the first stage.   
Mandrekar et al. [70] presented an adaptive design for two-agent Phase I trials based on 
an extended continuation ratio model  from the single-agent “TriCRM design” proposed by 
Zhang et al. [71]. Three mutually exclusive and exhaustive outcomes are considered in their 
design: no response (no efficacy and no toxicity), success (efficacy and no toxicity) and toxicity. 
Note that this classification of outcomes regards response as irrelevant if toxicity occurs. Joint 
criteria based on both toxicity and success determine the dose combination for the next cohort. 
Huang et al. [72] introduced a novel parallel Phase I/II trial design for combined agents. There 
are three new aspects in their design: first, the trial begins with an initial dose-escalation period 
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based on the number of DLTs to select admissible dose combinations for testing; secondly, they 
randomize patients adaptively to all the admissible dose combinations with the assignment 
probabilities proportional to the credibility of the supposition that one dose combination is 
superior to the other ones; and thirdly, they perform interim monitoring for efficacy and toxicity 
to temporarily close dose combinations with lower efficacy and eliminate those with intolerable 
toxicity. The simulations show that their proposed design has better efficiency compared to the 
conventional designs. 
Wang and Day [73] presented a new adaptive Bayesian Phase I design using a joint dose 
thresholds model. Their design utilizes prior information about the joint toxicity and efficacy 
dose thresholds distribution as well as accumulating data. The dose chosen for each patient 
maximizes the current posterior expected personal utility. They provide four types of utility 
functions based on a patient’s bivariate outcome. Simulation shows that their design, compared 
to the standard design, identifies the right dose with smaller sample size and has more patients 
experiencing the desirable outcome (non-toxicity and efficacy responses) and fewer patients 
experiencing the undertreated outcome (non-toxicity and non-efficacy responses).    
2.2.3 Summary 
In this review, we have seen that the designs that people propose differ in many ways.  Among 
the most important is the degree to which they use available prior and ongoing information to 
choose each patient’s dose. The majority of the recently proposed designs continue to 
incorporate the Bayesian calculations in various ways. Increasingly the designs include an initial 
algorithm-based dose-escalation period when there is little prior information the drug under 
study.  
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3.0  EVALUATION CRITERIA FOR PHASE I DOSE-FINDING CLINICAL TRIAL 
DESIGNS 
Evaluation of CT designs is a very important procedure when planning a clinical trial, modifying 
trial designs in response to interim results, or comparing competing designs in methodology 
research. The choice of criteria for evaluation depends on the goal of the studies. For example, if 
the goal of a certain Phase I trial is to find OD as accurately as possible, one evaluation criterion 
might be bias of the RP2D. Since Phase I trials are usually first-in-human studies, evaluating 
operating characteristics of designs before running clinical trials is critically necessary from both 
ethical and scientific considerations. In this chapter, I review the existing evaluation criteria for 
Phase I dose-finding trial designs and introduce new criteria based on utility functions. 
3.1 EXISTING EVALUATION CRITERIA 
This section classifies evaluation criteria according to the inputs. 
3.1.1 Criteria that depend only on each patient’s outcome: 
• Number and/or proportion of toxicity responses 
• Number and/or proportion of efficacy responses  
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• Number and/or proportion of joint responses of toxicity and efficacy 
3.1.2 Criteria that depend only on each trial’s outcome: 
• Total number of included patients 
• Number and/or proportion of patients treated at each dose level  
• Number of cohorts to complete the trial. (The number of cohorts suggests the length of 
time to complete the trial when there are patients readily available for entry into the trial 
[74].) 
• Probability of a dose being chosen as the RP2D 
• Number and/or proportion of trials where no RP2Ds are determined 
• Number and/or proportion of patients treated at the OD given a pre-specified criterion 
• Number and/or proportion of patients treated below the OD given a pre-specified 
criterion 
• Number and/or proportion of patients treated above the OD given a pre-specified 
criterion 
• Variance of the  RP2Ds 
• Mean probability of having a toxicity response at the RP2D (It is called by Lin and Shih 
[75] target toxicity level) for algorithm-based designs.  
• Variance of the estimated probability of having a toxicity response at each dose level 
3.1.3 Criteria that depend on each trial’s outcome compared to the “truth”: 
The “truth” can be: 
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• True dose-toxicity response curve 
• OD given a pre-specified criterion 
• The true probability or odds of toxicity responses at the RP2D 
• Some optimal design used as gold standard 
Criteria that are interpretable as expected loss:  
• Mean absolute error of the RP2D compared to the OD 
• Mean absolute error of the true probability of toxicity responses at the RP2D compared to 
that at the OD 
• Proportion of the determined RP2Ds that are too low ( for example, Storer  [76] 
considered the determined RP2D too low when its odds of toxicity responses is less than 
half that of the OD) 
• Proportion of the determined RP2Ds that are too high ( for example, Storer  [76] 
considered the determined RP2D too high when its odds of toxicity responses is more 
than twice that of the OD) 
• Proportion of the inappropriately early terminated trials ( inappropriate early termination 
refers to the scenario that the trial has to be terminated because of the incorrect 
conclusion that the lowest testing dose is too toxic according to a pre-specified criterion) 
Curiously, to my knowledge, mean squared error hasn’t been used as a criterion in the Phase I 
design literature, even though it has an interpretation as an expected loss.  
Criteria that are not interpretable as expected loss:   
• Proportion of the trials where the OD are estimated correctly 
• Bias of the determined RP2D  compared to the OD given a pre-specified criterion 
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• Bias of the estimated probability of toxicity responses compared to the true probability of 
toxicity responses at each dose level 
• Efficiency of the design compared to another design considered optimal or ideal proposed 
by Paoletti et al. [77]. 
3.2 PROPOSED EVALUATION CRITERIA BASED ON UTILITY FUNCTIONS 
The above review of existing evaluation criteria did not reveal the use of evaluation criteria 
based on utility functions. Here, we propose flexible criteria for evaluating Phase I trial designs 
by assessing through CT simulation the expected total personal utility, societal utility and total 
utility. We acknowledge the challenge of developing a defensible and reasonable utility function 
that accounts for all the relevant risks and benefits. 
3.2.1 Expected total personal utility 
We define total personal utility as the total individual net benefit (less harm) experienced by 
patients on a particular clinical trial. We propose to measure the total personal utility by the sum 
of utilities associated with each participating patient’s outcome. Let PU stand for the total 
personal utility. Suppose that the total number of patients on a particular trial is n , their 
outcomes are 1,..., ny y , and the corresponding utilities associated with these outcomes are: 
1( ),..., ( )nu y u y . PU  is then calculated by: 
 
1
( )
n
P i
i
U u y
=
=∑  (1) 
 21 
For illustration, let us assume each patient has four possible outcomes: TE  (toxicity and 
efficacy responses), Te  (toxicity and non-efficacy responses), tE  (non-toxicity and efficacy 
responses) and te  (non-toxicity and non-efficacy responses). The corresponding utilities 
associated with these outcomes are ( ), ( ), ( ), ( )u TE u Te u tE u te  respectively. Table 3.1 lists four 
types of utility functions of the outcomes. The simple utility function only considers the benefit 
obtained from the best outcome tE , and ignores the difference among the other three possible 
outcomes. The additive utility function assumes that the utilities of having a toxicity, non-
toxicity, efficacy, or non-efficacy response are -0.5, 0.5, 0.5, -0.5 respectively and that the utility 
of having joint responses (e.g. TE ) is the sum of the utilities of its respective responses. The 
aggressive utility function regards toxicity and non-toxicity responses as identical when a patient 
has an efficacy response, and it gives a penalty to having toxicity response only when a patient 
does not have an efficacy response. Whenever a patient has a toxicity response, the cautious 
utility function assigns the utility of -1 to the outcome. Note that all four types of utility function 
assign the utility of 1 to the best outcome ( tE ), and 0 to the outcome te . 
 
 
Table 3.1 Four Types of Utility Functions for the Bivariate Outcome 
 
Outcome TE Te  tE  te  
Simple Utility 0 0 1 0 
Additive Utility 0 -1 1 0 
Aggressive Utility 1 -1 1 0 
Cautious Utility -1 -1 1 0 
 
 
 
Let d ∈D  denote a particular design, m∈M denote a particular interoperable model 
family pair (population and outcome model families) where “interoperable” means that a 
population model family can provide patient characteristics that an outcome model family 
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requires, m m∈Λλ denote a vector of specific parameter values for model family pair m , and 
x X∈  refer to the observations (all patients’ outcomes, { , 1,..., }iy i n= ), in a particular clinical 
trial. PU  is a function of x , and x depends on the design, underlying outcome generation 
mechanism and underlying patient characteristics (relevant to the design and outcome generation 
mechanism). Therefore PU also depends on these three factors.   Figure 3.1 displays the simple 
dependence relationship among those quantities, where each arrow points to the dependent 
quantity. 
 
 
 
Figure 3.1 Dependence Diagram for the Total Personal Utility 
 
For simplicity, we assume observations and parameters are all continuous. Let ( )mπ λ λ  
denote the prior density function for mλ , and ( )m mπ denote the prior probability of model family 
m . The expected total personal utility for a design d is: 
 
( ) ( ) { ( ) ( | , , ) } ( )
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, where (in an abuse of notation) ( , , ) ( ) ( | , , )P m P mEU d m U x f x d m dx= ∫λ λ
X
 and 
( , ) ( , , ) ( )
m
P P m m mEU d m EU d m dπ
Λ
= ∫ λλ λ λ . 
We can follow the steps below to approximate ( )PEU d through the Monte Carlo 
simulation: 
For a design d  and a model family pair m , do steps 1 to 6: 
1. Sample nλ sets of parameters from the prior distribution ( )mπ λ λ : 
{ , 1,..., , }w wm m mw nλ= ∈Λλ λ? ?  
2. Simulate a clinical trial under , , wmd m λ? , and get observations dmwx  
3. Calculate the ( )P dmwU x using Equation (1) 
4. Repeat steps 2-3 rn times 
5. Repeat steps 2-4 for the rest sets of sampled parameters 
6. Calculate ,
1 1
1 1( , ) { ( )}
rn n
P P r dmw
w rr
U d m U x
n n
λ
λ = =
= ∑ ∑ , which is an approximation to 
( , )PEU d m  
Repeat steps 1-6 for the other possible model family pairs, then 
calculate ( ) ( , )P m P
m
U m U d mπ
∈
= ∑
M
, which is the approximate estimate of ( )PEU d . 
When m and mλ are known and fixed, the computation for the expected total personal 
utility would be greatly simplified and it can be approximated using Equation (3). An example 
will be given in Section 5.2. 
 P,r
1
1( | , ) ( ( ) | , )
rn
P m m
rr
EU d m U x d m
n
=
≈ ∑λ λ  (3) 
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3.2.2 Expected societal utility 
We define societal utility as the total net benefit from knowledge gained by the society after 
running a particular clinical trial, and we denote it as SU . The primary goal of a Phase I dose-
finding trial is to find/recommend a dose of a drug for the subsequent Phase II trial, with the 
hope that the drug at this dose can have the maximal efficacy probability while having tolerable 
toxicity probability. We propose to measure SU  by the utility associated with the chosen RP2D. 
Assuming RP2D is chosen from one of the testing doses, let †EP  and 
†
TP  denote the probability of 
efficacy and probability of toxicity at the RP2D respectively. The current standard treatment is 
the treatment that patients will typically receive if they are not enrolled in the Phase I clinical 
trials. A family of reasonable societal utility functions is a function of †EP  and 
†
TP  and it assigns 
the utility of 0 to the current standard treatment. Figure 3.2 shows the graphical display for a 
possible societal utility function of this family. The red point with higher †EP and 
†
TP corresponds 
to the probability pair from the current standard treatment. Another red point on the †EP axis is 
elicited from physicians and is assumed to have the same societal utility as the current standard 
treatment. These two red points define the reference line (here, we assume the contour lines are 
linear). Other lines are drawn parallel to this reference line within the two-dimensional 
domain 2[0,1] . The points on the same line have the same societal utility, the ideal point (1, 0) 
has the largest societal utility, and the societal utility of the probability pair gets smaller as it 
moves farther away from the ideal point. 
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Figure 3.2 Graphical Display for a Societal Utility Function 
 
Divergent opinions may arise with respect to the shape of the contour lines (linear or 
nonlinear) and the relationship between different contour lines (parallel or nonparallel). The 
investigation of that direction is out of the scope of this dissertation. Another tricky or 
challenging part in defining a societal utility function is the assignment of utilities to each 
contour line, which demands careful considerations of risks and benefits relative to the current 
standard treatment. Assuming the contour lines are parallel to each other, we propose a method 
to assign the utilities by adapting the method introduced by Thall and Cook [67]. Suppose q is a 
point on a contour line, and p is the point at which the line from the ideal point (1,0) to  q  
crosses the reference line. The utility assigned to that contour line containing q  is calculated by 
( ) / ( ) 1p qρ ρ − , where (.)ρ  denotes the Euclidean distance from a point in the contour line to the 
ideal point. The utility assigned to the reference line is 0. The contour lines closer to the ideal 
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point compared to the reference line have the positive utility, while the contour lines farther 
away from the ideal point have the negative utility. 
The chosen 2RP D from a Phase I clinical trial depends on the design and the 
observations, denoted by x• , which include all patients’ outcomes ( x ) and also their assigned 
doses. x•  depends on the design, the underlying model family pair m (population and outcome 
model families) together with associated parameter values mλ .  Let { , 1,..., }jz j J= =Z denote 
the set of all testing doses, and { , }T tNA NA
°
=Z  denote the set of possible missing values for 
2RP D  in which TNA  refers to missing value because of too toxic lowest dose and tNA  refers to 
missing value because of still safe highest dose. If 2RP D ∈Z , our proposed societal utility 
function is a function of  †EP  and 
†
TP , and 
† †( , )E TP P depends on the chosen 2RP D , underlying 
model family pair and its associated parameter values. Following the notation mentioned in 
Section 3.2.1, we draw Figure 3.3 which displays the dependence relationship among those 
quantities.  
 
 
 
Figure 3.3 Dependence Diagram for the Societal Utility 
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For a design d , model family pair m and its parameter values mλ , the expected societal 
utility ( , , )S mEU d m λ is: 
 
† †( , , ) Pr( 2 | , , ) ( , | 2 , , )
                          Pr( 2 | , , ) ( 2 )
S m m S E T m
z
m S
z
EU d m RP D z d m U P P RP D z m
RP D z d m U RP D z
°
∈
∈
= = = +
= =
∑
∑
λ λ λ
λ
Z
Z
 (4) 
If we take expectation of ( , , )S mEU d m λ over M (the set of all possible m ’s) and mΛ (the space 
for mλ ), we can get the expected societal utility for a design d : 
 ( ) ( ) ( , , ) ( )
m
S m S m m m
m
EU d m EU d m dπ π
∈ Λ
= ∑ ∫ λλ λ λ
M
 (5) 
We can follow the steps below to approximate ( )SEU d through the Monte Carlo 
simulation: 
For a design d  and a model family pair m , do steps 1 to 6: 
1. Sample nλ sets of parameters from the prior distribution ( )mπ λ λ : 
{ , 1,..., , }w wm m mw nλ= ∈Λλ λ? ?  
2. Simulate rn clinical trials under , ,
w
md m λ?  
3. Calculate ? ( 2 )Pr( 2 )    , 
r
n RP D zRP D z z
n
°
=
= = ∈ ∪Z Z   
4. Repeat steps 2-3 for the rest sets of sampled parameter values 
5. Calculate:  
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Repeat steps 1-5 for the other possible model family pairs, then 
calculate ( ) ( , )S S
m
U m U d mπ
∈
= ∑
M
, which is the approximate estimate of ( )SEU d . 
3.2.3 Expected total utility 
We have seen that there are at least two radically distinct kinds of utility to contemplate 
when choosing a CT design. A third kind is the utility of total cost on a particular trial and we 
denote it as CU ( 0CU < ). The total cost includes, among others, the payment to enrolled patients, 
the cost for dose administration, medical management, data collection, and whatever penalties 
accrue from delayed reporting and publishing. We assume CU depends solely on sample size.  
To make a choice of designs, one cannot safely neglect any of these three kinds of 
utilities, therefore, there needs to be a way to view and think about all in one context. We 
propose two ways to do this. The first way is to calculate the expected total personal utility 
( PEU ), societal utility ( SEU ) and utility of total cost ( CEU ) for all candidate designs and 
summarize them in a two-way table, for example, Table 3.2.  Let TotU denote total utility that 
encompasses total personal utility, societal utility and utility of total cost on a particular trial. 
TotU  is a function of these three kinds of utilities whose special case is a linear function defined 
as:  
 Tot P P S S C CU U U Uν ν ν= + +  (6) 
, where the ν ’s are parameters which convert among the different kinds of utilities. The second 
way is to calculate the expected total utility ( TotEU ) for all candidate designs. Both ways have 
challenges in trading off among different kinds of utilities. The first way provides a transparent 
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view of the expected total personal utility, societal utility and utility of total cost for each 
candidate design, but CT designers have to do further analysis when no designs have the largest 
values across different kinds of expected utilities; the second way gives a convenient summary 
metric for comparing different designs, however, it may lead to a wrong decision when the 
justification for TotU function is questionable. In practice, CT designers may do both ways and 
make a choice from a careful consideration of risks and benefits. 
 
Table 3.2 A Two-way Table for Different Kinds of Expected Utilities 
 
 
Expected Utility 
PEU  SEU  CEU  
Design 
1 1 2.5 -2000 
2 -2 4.3 -3000 
3 2 0 -1000 
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4.0  CTDESIGNEXPLORER – AN ACTION QUEUE-BASED OPEN-SOURCE 
SIMULATION EXPERIMENT PLATFORM FOR EVALUATING CLINICAL TRIAL 
DESIGNS 
4.1 INTRODUCTION 
In the past few decades, clinical trial (CT) designers have proposed many designs for trials at 
different stages of drug development. This abundance of designs mandates a question for the 
investigators and statisticians planning a trial: what design would be the “best” for their trial? 
Determining the answer must begin with careful consideration of the sometimes conflicting 
criteria (e.g. number of adverse events vs. number of efficacy responses) by which to judge 
designs. 
Evaluating CT designs via simulation is used by academic research centers and 
pharmaceutical companies to improve the efficiency and accuracy of drug development [1-4]. 
Sophisticated commercial software for CT simulation and evaluation is available for those with 
resources to cover fees and with design challenges that happen to match the software’s 
capabilities. The source code of commercial software is proprietary, so users cannot easily verify 
the software does what it claims. Academic research centers usually use locally developed 
software mainly due to cost and flexibility considerations. The cost issue is illustrated by the 
recent quote price of a one-year single academic license for the Pharsight trial simulator: 
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$11,235. Flexibility makes it possible to explore novel designs, models and evaluation criteria. 
Software developed locally focuses on answering specific research questions in compressed 
time, and therefore has limited capabilities. The open-source software development approach has 
helped produce reliable, high quality software quickly and inexpensively. To our knowledge, 
MSToolkit is the only currently available open-source software for general-purpose CT design 
evaluation via simulation. It provides flexible data handling, however, it also falls short in 
capabilities; for example, it cannot evaluate designs with adaptive treatment allocations in its 
most recent version 2.0.  
The lack of a common framework for describing CT environments and standards for 
coding leads to information and software resource silos, constricting exchanges of ideas and data 
between innovative CT designers and those selecting existing designs for CTs. Lack of 
interoperability is a root cause of inefficient design evaluation processes and inconsistent 
evaluation results.  
Therefore, we seek to build a transparent, extendible simulation experiment platform and 
a set of standards for further development so that CT designers can evaluate available designs 
and/or share their innovations. Here we introduce CTDesignExplorer - an open-source platform 
based on an action queue, with reliance on common names of the data elements to support 
interoperability.  Techniques in S4 classes and methods [78] are utilized to make 
CTDesignExplorer extendible and reusable. To facilitate the use, we have developed 
CTDesignExploer as an R package. In Section 4.2, we will describe CTDesignExplorer in detail 
and illustrate extensibility, reuse and sharing using some examples, and in Section 4.3 we 
conclude with future development. 
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4.2 CTDESIGNEXPLORER 
4.2.1 Overview 
Specification of a simulation experiment requires users to specify objects in the following five 
categories: 
Design 
A design is an algorithm for making decisions in a CT. The types of decisions include 
allocating a treatment plan to each patient cohort, switching from the first stage of a CT to the 
second stage (e.g. adaptive Simon two-stage design [79]), conducting assays and other data 
collection actions, and stopping or continuing a CT. A design specification includes both the type 
of design and a specific value for a vector of design parameters.  
Baseline Characteristic Model 
A baseline characteristic model is a description of the sampling distribution for one 
baseline characteristic of a patient. A patient’s baseline characteristics may be dependent on each 
other. To model the total joint distribution of a patient’s baseline characteristics, we model each 
baseline characteristic using sequential conditional distributions. A baseline characteristic model 
specification includes the baseline characteristic name, the names of other baseline 
characteristics and a function for generating the baseline characteristic. It does not include 
whether and when the baseline characteristic is to be measured; instead, that is determined by the 
design. 
Population Model 
A population model is a description of the joint distribution of all baseline characteristics 
that may affect either the patient’s outcomes, times to outcomes, or patient-level decision-
 33 
making in a CT. A population model specification is a list of baseline characteristic model 
specifications.    
Outcome Model 
An outcome model is a rule for generating a patient’s outcomes and/or times to outcomes, 
as a function of his/her baseline characteristics, treatment plan allocations and previous 
outcomes. An outcome model specification includes the type of outcome model and specific 
values for a vector of model parameters.    
Evaluation Criterion 
An evaluation criterion refers to an operating characteristic of a design. An evaluation 
criterion specification may include specific values for a vector of criterion parameters if any. 
 
 
 
Figure 4.1 Overview of CTDesignExplorer 
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Figure 4.1 displays the overview of CTDesignExplorer. To perform a simulation 
experiment, users need to provide the specifications for objects: designs, population models, 
outcome models and evaluation criteria of interest. After CTDesignExplorer receives the inputs 
from users, including the number of CT simulations, it automatically checks what objects can 
interoperate with each other (interoperability among objects will be discussed in Section 4.2.3). 
Each combination of a design, population model and outcome model constitutes a scenario. For 
each scenario, CTDesignExplorer runs N CT simulations, and the simulated CT data are 
evaluated by the corresponding criteria. After simulation and evaluation are done for all 
scenarios, the evaluation results are displayed in the user interface. 
Users can also save simulated data to a specified directory, together with the seed for 
random number generations to allow replication of results. 
4.2.2 Simulation framework 
Figure 4.2 displays the framework we use for simulating a single CT at a certain scenario. An 
action queue is a list of actions ordered by their execution times. The solid dark arrows trace 
simulation steps in the framework; the blue dotted arrows show action exchanges between the 
action queue and steps; the green dotted arrows show data exchanges between the temporary CT 
data repository and steps. At the start of the simulation, the framework initializes a temporary CT 
data repository and an action queue. The initial actions in an action queue are generated by a 
design object. After initialization, the “while” loop begins. On each round, the first action in the 
queue is retrieved, executed and removed from the queue. The consequences from executing an 
action may include adding new actions to the queue and/or adding new data to the CT data 
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repository. If the queue is now empty, the simulation stops, otherwise the “while” condition is 
satisfied, and the loop continues.  
 
 
 
Figure 4.2 Action Queue-based Simulation Framework 
 
The action queue-based framework is particularly useful in simulating CTs where 
decisions, either at the patient level or at the CT level, depend in complex ways on the current 
state of information. For example, in some CT designs, the protocol’s treatment of a patient may 
change while on study due to a crossover design element, a rule for dosage modification or delay 
due to toxicity, or a secondary randomization.  Also, patient histories may overlap, which 
complicates the application of stopping rules or treatment allocation rules.  The action queue 
handles all these cases.  It adds new actions adaptively, as needed, guided by accumulating data. 
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4.2.3 Interoperability 
 
 
 
Figure 4.3 Communications among Objects 
 
In CTDesignExplorer, objects (designs, baseline characteristic models, population models and 
outcome models) may require information provided by other objects to perform their functions. 
Thus, in our terminology, the information that an object provides is called provisions and the 
information that an object requires is called requirements. As displayed in Figure 4.3, baseline 
characteristic models are nested within a population model as a whole to communicate with other 
types of objects. The population model provides values of baseline characteristics to the outcome 
model, design and evaluation criterion; the outcome model provides outcomes (possibly 
including time-to-event data) to both the design and the evaluation criterion; the design provides 
treatment allocations to both the outcome model and the evaluation criterion, additionally, the 
design provides summary results (conclusions) from running a CT and CT times to the 
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evaluation criterion. CT time is the time at which a CT-level event occurs, for example, time 
when a CT ends. In Figure 4.3, arrows point to requirers and away from providers. 
We have providers and requirers communicate using common names of the data 
elements. Examples of these data elements along with their common names are presented in 
Table 4.1. 
We use a name matching mechanism to check interoperability between requirers and 
providers. For example, if a design requires “BinaryToxicity” outcomes and an outcome model 
provides “ToxicityGrade” outcomes, this design does not interoperate with this outcome model, 
because it requires binary toxicity outcomes and the outcome model provides ordinal toxicity 
outcomes. 
 
Table 4.1 Examples of Common Names for Data Elements 
 
Provided by Type Name Definition PossibleValues
Population Model Baseline 
characteristic 
SubPopIndex Which sub-population 
a patient belongs to 
1, 2, 3… 
Design An element of a 
treatment allocation
Dose The dosage of a 
treatment 
≥ 0 
Design Conclusion         RP2D Recommended Phase II 
dose 
> 0, NA 
Design CT time CTEndTime Time when a CT ends ≥ 0, NULL 
Outcome Model Outcome BinaryToxicity Indicator whether a 
patient experiences a 
dose-limiting toxicity 
(DLT) 
0, 1 
Outcome Model Outcome ToxicityGrade Ordinal toxicity 
outcome, as a grade 
1,2,3,4,5 
Outcome Model Time to outcome TimeToToxicity Time to a DLT event ≥ 0 
 
 
 
To facilitate use of common names of the data elements and to promote contributions 
from a wide community of CT designers, we will develop similar interactive tools to “CDE 
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Browser” and “CDE Curation Tool” used in the cancer Data Standards Registry and Repository 
(caDSR) for browsing and managing the common data elements. 
4.2.4 Implementation: S4 classes and methods 
We designed and implemented CTDesignExplorer using the object oriented programming (OOP) 
paradigm. OOP encapsulates the representation of objects, which helps to modularize a complex 
software system; it also provides class inheritance and method-dynamic dispatch, which makes it 
possible to both build a common framework and extend the software for innovations. The code 
base relies on S4 classes and methods [78] within R. S4 OOP is slightly different from traditional 
OOP other languages like Java and Python follows, in that the method definitions in the S4 
system do not reside in a class definition. Instead, methods having the same name are stored 
within the same generic function according to their signature, a named list of classes with the 
names corresponding to the arguments’ names of the generic function.  
An S4 class is declared by a call to setClass, along with the named slots which 
contains relevant information. The instances of a class are validated against its definition. An S4 
method cannot be declared by a call to setMethod unless its corresponding generic function 
has been declared using the setGeneric function. In the following, we will show the 
representations of the objects in CTDesignExplorer by S4 classes and methods. 
For baseline characteristic models, the class “BaseCharModelSpecifier” represents their 
specifications and an associated method for generating a single patient’s baseline characteristic.  
For population models, the class “PopModelSpecifier” represents their specifications, and 
there are two associated methods. One method sequentially generates each of a patient’s baseline 
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characteristic values, and the other method generates these values for a specified number of 
patients. 
For a specific type of designs, a subclass of the virtual class “DesignSpecifier” represents 
their specifications, and there are associated methods for each type of decision, such as allocating 
a set of concurrent treatments.  
For a specific type of outcome models, a subclass of the virtual class 
“OutcomeModelSpecifier” represents their specifications, and there are two associated methods. 
One method generates a patient’s outcomes and/or times to outcomes from a set of concurrent 
treatments, and the other method generates outcomes and/or times to outcomes from a set of 
concurrent treatments for a specified group of patients.    
For a specific type of evaluation criteria, a subclass of the virtual class “EvalSpecifier” 
represents their specifications, and there is one associated method for evaluating a design under 
this type of criteria. 
Additionally, there are methods for getting provisions and/or requirements from designs, 
baseline characteristic models, population models, outcome models and evaluation criteria. 
Data from a single CT simulation are represented by the class “CTData”. Figure 4.4 
illustrates the hierarchical data structure. Each patient’s data is represented by the class 
“PatData”, and data from each set of concurrent treatments are represented by the class 
“ConcurrentTrtsData”. A default object instantiated from the class “CTData” has an empty list 
for “PatsData” slot, values of NULL for both CT times and conclusions. 
Actions in an action queue are represented by the class “Action”. Each action object 
contains information for calling the corresponding method and the time when it is executed. An 
example of the corresponding method to an action is allocateTrts, which returns a named 
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list of two elements: one is the updated CT data with new treatment allocations information for a 
specified group of patients, and the other is a list of new actions (e.g. a new action can be 
generating this group of patients’ outcomes after the treatment). Only methods associated with 
designs can be action methods. Action queues are represented by the class “ActionQueue”. Its 
associated method addAction inserts a new action to the right position of the queue, and 
returns the updated action queue. 
 
 
 
Figure 4.4 CT Data Structure 
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4.2.5 Regular use: using existing classes and methods 
Regular use refers to using only already exisiting classes and methods in the CTDesignExplorer 
release. The essence of the flexibility in evaluating designs using our platform is that it allows 
for different population models, outcome models and evaluation criteria. We list below some use 
cases of interest to colleagues. The uses of CTDesignExplorer are not limited to these examples. 
• A protocol statistician worries about the potential adverse effect of patient heterogeneity 
in the accrual pool on the performance of a Phase I dose-finding design. The statistician 
specifies population models for a Phase I patient population with and without 
heterogeneity respectively; specifies the Phase I trial design he/she cares about; specifies 
a plausible underlying true outcome model; specifies the evaluation criteria that are used 
to assess performance of the design; runs the experiment with these inputs and then 
compares the evaluation results between the scenarios using different population models. 
This use case is demonstrated in Section 5.2. 
• An investigator has concerns about the cost-effectiveness of genotyping patients for 
identifying a certain allele which may affect a patient’s outcome on treatment due to 
pharmacokinetic or pharmacodynamic effects. The investigator specifies a population 
model for a patient population with a specified proportion of patients having that allele; 
specifies the two designs, one accounts for and the other disregards that genetic 
information; specifies a plausible underlying true outcome model in which whether or 
not having that gene is a dichotomized covariate; specifies the evaluation criteria that can 
be used to estimate the cost-effectiveness, such as expected total utility; runs the 
experiment with these inputs and compare the evaluation results between two designs. 
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• A research statistician is interested from a methodological perspective in investigating 
how different choices of prior distribution for parameters in the assumed logit dose-
toxicity model affect the performance of CRM designs. He/she specifies a population 
model for a patient population if necessary; specifies the CRM designs which are only 
different with respect to the prior distributions; specifies several true outcome models; 
specifies the evaluation criteria to assess the performance of the designs; runs the 
experiment with these inputs and compares the evaluation results between these designs. 
This use case is demonstrated in Section 5.1.4. 
Users do not need to know S4 classes and methods in order to use CTDesignExplorer and 
conduct simulation experiments. We provide the interfacing function “specifyObject” which 
allows users to specify a baseline characteristic model, population model, outcome model, design 
and evaluation criterion using a regular R function. The following shows an example on how to 
specify a standard Phase I “3+3”design: 
First, find all available classes for representing a design specification 
> subClassNames("DesignSpecifier") 
[1] "APlusBSpecifier"          
[2] "CRMSpecifier" 
[3] "Phase2BryantDaySpecifier" 
 
The “APlusBSpecifier” class represents specifications for “A+B” with dose de-escalation 
designs [75], of which the “3+3” design is a special case. 
Second, obtain documentation on class “APlusBSpecifier” 
> class?APlusBSpecifier 
An HTML window will pop up for the documentation part of which is shown in Figure 4.5. 
Finally, specify a “3+3” design 
> specifyObject( 
+ className="APlusBSpecifier", 
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+  slots=list(A=3,B=3,C=1,D=1,E=1,TierDoses=c(3.0,6.0,9.9,15.0 
+           ,21.1,28.0) 
+ ) 
An object of class “APlusBSpecifier” 
Slot "A": 
[1] 3 
Slot "B": 
[1] 3 
Slot "C": 
[1] 1 
Slot "D": 
[1] 1 
Slot "E": 
[1] 1 
Slot "TierDoses": 
[1]  3.0  6.0  9.9 15.0 21.1 28.0 
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Figure 4.5 Partial Documentation for Class "APlusBSpecifier" 
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4.2.6 Advanced use: extending, reusing and sharing 
Advanced use refers to extending our platform, reusing code for already existing specifierObject 
classes, and sharing innovations with a community of CT designers.  
4.2.6.1 Extending 
Since we allow users to write their own functions for generating a baseline characteristic when 
specifying a baseline characteristic model, CTDesignExplorer can cover any user-defined 
baseline characteristic model and population model. Users can extend CTDesignExplorer for 
their novel designs, outcome models and evaluation criteria by developing new subclasses and 
the associated methods. We provide templates for users to follow when extending the software 
for different types of innovations. For example, the following lists the templates for extending 
CTDesignExplorer for a new design. The bold italics and “xxx” in the templates will be 
substituted by users. 
• To develop a new subclass of class “DesignSpecifier” for the new design specification, 
this template is used: 
setClass(“NewDesignSpecifier”,  
representation(DesignParam1=xxx, DesignParam2=xxx, xxx), 
contains=”DesignSpecifier”, 
prototype=list(xxx),  
validity=function(object){xxx}) 
 
For example, if this new design is a CRM design [6], “NewDesign” in the above template can be 
substituted by “CRM”. 
 
• To develop associated methods for the new design, these templates are used: 
setMethod("generateInitialActions", 
signature(designSpec="NewDesignSpecifier"), 
function(designSpec){xxx}) 
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The above method returns a list of initial actions. 
The returned value from each of the methods below is a named list with at most two 
elements: the element with name “NewCTData” stores the updated CT data; and the element 
with name “NewActions” stores a list of new actions. 
setMethod("allocateTrts", 
signature(designSpec="NewDesignSpecifier", 
currentCTData="CTData", 
currentGlobalTime=”numeric”, 
patsIndices="numeric”), 
function(designSpec,currentCTData,currentGlobalTime,patsInd
ices){xxx}) 
 
The above method returns a named list with two elements. 
setMethod("checkStoppingRule", 
signature(designSpec="NewDesignSpecifier", 
currentCTData="CTData", 
currentGlobalTime=”numeric”), 
function(designSpec,currentCTData,currentGlobalTime){xxx} 
 
The above method returns a named list with one element; that element’s name is either 
“NewCTData” (if the stopping rule decides to stop the CT) or “NewActions” (if the stopping 
rule decides to continue the CT). 
setMethod("checkSwitchingStageRule", 
signature(designSpec="NewDesignSpecifier", 
currentCTData="CTData", 
currentGlobalTime=”numeric”), 
function(designSpec,currentCTData,currentGlobalTime){xxx} 
 
The above method is optional, depending on whether the new design is multiple-stage design. It 
returns a named list with updated CT data. If the switching-stage rule decides to switch the 
current stage of a trial to a higher stage, the “SwitchingStageTime” would be changed from 
NULL to the current global time. 
The new design may have more associated methods, e.g. for checking off-CT rule. Then 
users need to develop a generic function first and then the method.  
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• To develop methods for getting provisions and requirements of the new design, the 
following two templates are used. 
setMethod("getProvisions", 
signature(spec="NewDesignSpecifier"), 
function(spec){xxx}) 
 
The above method returns a named list with elements for the names of treatment allocation 
elements, CT times and conclusions that the new design provides. 
setMethod("getRequirements", 
signature(spec="NewDesignSpecifier"), 
function(spec){xxx}) 
 
The above method returns a named list with elements for the names of baseline characteristics, 
outcomes and times to outcomes that the new design requires. 
4.2.6.2 Reusing 
The class inheritance central to object-oriented programming greatly facilitates the reuse of code 
for already existing specifierObject classes in the CTDesignExplorer release. Subclasses of a 
class inherit all the methods associated with that class, and R provides mechanisms to select a 
method based on inheritance distance[78]. For example, if the algorithm of the new design for 
allocating a set of concurrent treatments is the same as that of an existing design, instead of 
developing a subclass of “DesignSpecifier” in the first template above, users can reuse the code 
for implementing that algorithm by developing a subclass of the class for the existing design 
specification. 
4.2.6.3 Sharing 
 Users have the following two options for sharing their innovations after developing new classes 
and associated methods: 
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• Submit their codes to us, and we will include them in the next version of 
CTDesignExplorer if the submission meets a set of requirements (e.g. requirements for 
validation and documentation) 
• Develop a small new R package which depends on CTDesignExplorer, to be released 
independently. 
4.2.7 Code Validation 
Code validation after implementation is an important step to assure users of the quality of 
software. In the spirit of open-source software (OSS) – “given enough eyeballs, all bugs are 
shallow” [80], the intent and hope is to rely heavily on peer code review for an overall 
improvement of the quality of software. To facilitate this process, we plan to register a project 
for CTDesignExplorer on R-Forge [81] which offers a central platform  for the development of R 
packages, R-related software and other projects. R-Forge provides quality management system 
similar to that of CRAN which checks packages based on R CMD check at least once daily; it 
also provides bug tracking system which allows users to notify package authors about the 
problems they encounter.  
Before we release new version of CTDesignExplorer, we will validate code for new 
subclasses and methods provided by either us or contributors. Two ways can be used for 
validating the code for new subclasses and methods associated with outcome models and 
evaluation criteria: one way is to implement new outcome models in S3 system and to compare 
results obtained from the two kinds of implementation; another way is to ask a third person to 
examine the code. 
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For new subclasses and methods associated with a design, we will first find other 
software which implements the same design. If the other software is available, we will compare 
two things: one replication of the simulated clinical trial data and evaluation results under certain 
criteria, obtained from the other software with those obtained from the new subclasses and 
methods. If the other software is not available, we will ask a third person either to examine the 
code or to write code for implementing such design in S3 system and then we will compare 
his/her simulated data and evaluation results with those from the new subclasses and methods. In 
the following, we will give two examples demonstrating code validation for subclasses and 
methods associated with designs. 
4.2.7.1  Code validation for “A+B” design 
Yong Lin has written the “pmtd” program for numeric calculation of the evaluation criteria 
discussed in his paper “Statistical Properties of the Traditional Algorithm-based Designs for 
Phase I Cancer Clinical Trials”[75]. The ‘pmtd” program is available from 
“http://www2.umdnj.edu/~linyo/”. Even though the “pmtd” is an S-plus program, we can run it 
without any modifications in the R environment. The “A+B” design implemented in 
CTDesignExlporer corresponds to the “A+B” design with dose de-escalation in Lin’s paper. We 
did not find publicly available software for simulating data from clinical trials using the “A+B” 
design. 
To compare our evaluation results with the analytical results from the “pmtd” program, 
we performed a simulation experiment for the standard “3+3” design. The experiment is set up as 
below: 
Design: the standard “3+3” design 
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Population Model: None. We assume there are no individual’s baseline characteristics that will 
affect the patients’ outcomes. 
Outcome Model: a non-parametric dose-toxicity model. The corresponding toxicity probabilities 
to the testing tier doses are listed in the table below: 
 
Table 4.2 The Outcome Model Used in the Code Validation for “A+B” Design 
 
Tier Dose 3.0 6.0 9.9 15.0 21.1 
Pr(T) 0.05 0.1 0.15 0.25 0.4 
 
 
Evaluation Criteria: 
• Probability of each tier dose being chosen as RP2D 
• Average number of patients allocated at each tier dose 
• Average number of toxicities observed at each tier dose 
Number of Simulations: 1000 
In the next, we will look at the comparison results. For simplicity, we abbreviate 
CTDesignExplorer as CTDE in the following tables within this section and Section 4.2.7.2. 
We denote the chosen RP2D as tNA if dose escalation is still indicated at the highest tier 
dose, and as TNA if dose de-escalation is indicated at the lowest tier dose. Table 4.3 shows the 
first comparison result on the probability of each tier dose being chosen as RP2D; Table 4.4 
shows the second comparison result on the average number of patients allocated at each tier 
dose; and Table 4.5 shows the third comparison result on the average number of toxicities 
observed at each tier dose. 
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Table 4.3 First Comparison Result in the Code Validation for “A+B” Design 
 
 RP2D 
3.0 6.0 9.9 15.0 21.1 tNA  TNA  
CTDE 0.081 0.178 0.321 0.283 0 0.116 0.021 
Pmtd 0.095 0.175 0.305 0.265 0 0.133 0.027 
(CTDE –pmtd)2/pmtd2 0.022 <0.001 0.003 0.005 NA 0.016 0.049 
Chi-Squared Test 
• The test is comparing the observed frequencies of each tier 
dose being chosen as RP2D except for the dose of 21.1 in 
CTDE against the calculated probabilities from pmtd. 
• P value: 0.17  
 
 
Table 4.4 Second Comparison Result in the Code Validation for “A+B” Design 
 
 Tier Dose 3.0 6.0 9.9 15.0 21.1 
CTDE 3.630 4.107 4.347 3.825 1.803 
pmtd 3.658 4.062 4.231 3.689 1.850 
(CTDE –pmtd)2/pmtd2 <0.001 <0.001 0.001 0.001 0.001 
Chi-Squared Test 
• The test is comparing the average number of 
patients allocated at each tier dose in CTDE 
against the calculated probabilities from pmtd. 
• P value: 0.9994 
 
 
Table 4.5 Third Comparison Result in the Code Validation for “A+B” Design 
 
 Tier Dose 3.0 6.0 9.9 15.0 21.1 
CTDE 0.132 0.384 0.658 0.956 0.754 
pmtd 0.183 0.406 0.635 0.922 0.740 
(CTDE –pmtd)2/pmtd2 0.078 0.003 0.001 0.001 <0.001 
Chi-Squared Test 
• The test is comparing the average number of 
toxicities observed at each tier dose in CTDE 
against the calculated probabilities from pmtd. 
• P value: 0.93 
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We found from the above comparisons that the evaluation results for the standard “3+3” 
design using CTDesignExplorer are very similar to those analytically calculated results from 
“pmtd” program. 
4.2.7.2 Code validation for the CRM 
We compared one replication of CT data (patient Level: binary toxicity outcome and the 
assigned dose level; CT level: recommended Phase 2 dose level (RP2DL)) and evaluation results 
from 1000 simulations with those obtained from another R package “dfcrm”, which can be 
downloaded from CRAN.  
Specifically, we consider 16 different CRM designs as described in the table below: 
 
Table 4.6 Designs Used in the in the Code Validation for the CRM 
 
Design # Model Type Restriction # Stage Cohort Size 
1 Exponential Yes One 1 
2 Exponential Yes One 2 
3 Exponential Yes Two 1 
4 Exponential Yes Two 2 
5 Exponential No One 1 
6 Exponential No One 2 
7 Exponential No Two 1 
8 Exponential No Two 2 
9 Logit Yes One 1 
10 Logit Yes One 2 
11 Logit Yes Two 1 
12 Logit Yes Two 2 
13 Logit No One 1 
14 Logit No One 2 
15 Logit No Two 1 
16 Logit No Two 2 
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In the above table, Model Type refers to type of the assumed one-parameter dose-toxicity 
model; Restriction refers to the dose escalation restriction proposed by Cheung in his “dfcrm” 
package which avoids (1) skipping doses in escalation and (2) escalating when the proportion of 
patients experiencing toxicity in the last patient cohort is larger than or equal to the target 
toxicity rate (i.e., incoherent escalation); two-stage CRM includes an initial stage where the dose 
level is escalated according to a pre-specified dose level sequence. 
These 16 CRM designs share the following design parameters: 
• Initial toxicity probability guesses: 0.04, 0.12, 0.16, 0.23, 0.44 
• Tier doses:3.0, 6.0, 9.9, 15.0, 21.1 
• Target toxicity rate: 0.15 
• Sample Size: 24 
• Starting dose level if the design is one-stage CRM: 2 
• Dose level assignment sequence in the initial stage if the design is two-stage CRM are: 1, 
1, 1, 1, 2, 2, 2, 2, 3, 3, 3, 3, 4, 4, 4, 4, 5, 5, 5, 5, 5, 5, 5, 5.  
• The intercept value for the logit model = 3 
• The prior distribution is normal with mean 0 and standard deviation 1.34 
The population and outcome models, and evaluation criteria are the same as those in 
Section 4.2.7.1. 
The R functions used for generating random numbers in the CRM design implementation 
are the same between CTDE and “dfcrm”, and we use the same initial seed for random number 
generations when running experiments. Assuming “dfcrm” code is valid, we expect the one 
replication of CT data and evaluation results from 1000 simulations obtained from CTDE would 
be the same as those from “dfcrm” if CTDE code is valid.  
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We will now look at the simulation results obtained from CTDE and “dfcrm” when CT 
design is design 1: 
• One replication of CT data 
 
Table 4.7 First Comparison Result in the Code Validation for the CRM 
 
Patient ID CTDE dfcrm Toxicity  Assigned Dose Level Toxicity Assigned Dose Level 
1 0 2 0 2 
2 1 3 1 3 
3 0 1 0 1 
4 0 1 0 1 
5 1 1 1 1 
6 0 1 0 1 
7 0 1 0 1 
8 0 1 0 1 
9 0 1 0 1 
10 0 1 0 1 
11 1 1 1 1 
12 0 1 0 1 
13 0 1 0 1 
14 0 1 0 1 
15 0 1 0 1 
16 0 1 0 1 
17 0 1 0 1 
18 0 1 0 1 
19 0 1 0 1 
20 0 1 0 1 
21 0 1 0 1 
22 0 1 0 1 
23 0 1 0 1 
24 0 1 0 1 
RP2DL 1 1 
 
 
• Probability of each tier dose being chosen as RP2D 
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Table 4.8 Second Comparison Result in the Code Validation for the CRM 
 
 RP2D 
3.0 6.0 9.9 15.0 21.1 
CTDE 0.109 0.307 0.308 0.248 0.028 
dfcrm 0.109 0.307 0.308 0.248 0.028 
 
 
• Average number of patients allocated at each tier dose 
 
Table 4.9 Third Comparison Result in the Code Validation for the CRM 
 
 Tier Dose 3.0 6.0 9.9 15.0 21.1 
CTDE 4.382 6.053 5.582 5.72 2.263 
dfcrm 4.382 6.053 5.582 5.72 2.263 
 
 
• Average number of toxicities observed at each tier dose 
 
Table 4.10 Fourth Comparison Result in the Code Validation for the CRM 
 
 Tier Dose 3.0 6.0 9.9 15.0 21.1 
CTDE 0.21 0.573 0.849 1.439 0.898 
dfcrm 0.21 0.573 0.849 1.439 0.898 
 
 
The above tables show no difference in both the simulated data and evaluation results 
between CTDE and “dfcrm”.  We did not observe differences for the other 15 designs as well 
(we omitted the tables here). 
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4.3 FUTURE DEVELOPMENT 
We present an open-source simulation experiment platform for evaluating competing CT 
designs. An R package called CTDesignExplorer has been developed based on the source code 
as of April 30th, 2010. Future development will include setting up requirements for contributors, 
publishing CTDesignExplorer, project registration on R-Forge to facilitate collaborative software 
development and building a user-friendly GUI. Complex factorial evaluations will be 
computationally time-consuming. Parallelization for these demanding tasks is possible, for 
example, several R packages provide support for parallel processing [82].   
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5.0  SOFTWARE APPLICATION IN EVALUATING EARLY PHASE CLINICAL 
TRIAL DESIGNS  
Simulation allows CT designers to assess the consequences of the design factors and the 
assumptions made. The purpose of this chapter is to present several examples of using the 
platform to investigate important issues in model formulation, choice of prior distributions, and 
patient heterogeneity for early phase clinical trial designs. Specifically, we will look at the logit 
model in the continual reassessment method (CRM), choices of prior distribution for its model 
parameters, and the effect of patient heterogeneity on the performance of the standard “3+3” 
design and the CRM. 
5.1 LOGIT MODEL IN THE CONTINUAL REASSESSMENT METHOD 
5.1.1 The continual reassessment method (CRM) 
The CRM  was first introduced by O’Quigley et al. in the year 1990 [6], and has drawn much 
attention from the biostatistical community [7-14]. The CRM assumes that the probability of 
toxicity response increases monotonically with increasing dose via a parametric model 
*( | )j jp p z φ= , where j is the index for tier dose level, φ is a vector of parameters that can be of 
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length one or more than one, jp is the toxicity probability at tier dose level j , and 
*
jz  is very 
rarely the actual therapeutic dose, but rather is a rescaled dose at level j , calculated from the 
initial guesses of toxicity probabilities ( , 1,...,j j Jπ = ) and prior means of parameters ( 0φ ). 
Substituting jp  by jπ , and φ  by 0φ  into the chosen parametric model, we can find a solution 
for *jz  that is assigned to tier dose level j . Commonly used models include the conventional 
logit model (“conventional” is used to distinguish this model from the re-parameterized logit 
model to be introduced in Section 5.1.2) 
 *log( ) exp( )
1
j
j
j
p
z
p
α β= +
−
 (7) 
, and the exponential model: 
 * exp( )( )j jp z
β
=  (8) 
In CRM, the dose-toxicity response relationship is continually re-assessed based on 
accumulating data collected from the trial. The next patient cohort is typically assigned the dose 
which has the posterior toxicity probability closest to the target toxicity rate, although the next 
patient cohort can receive the highest dose with the posterior toxicity probability lower or equal 
to the target toxicity rate in some trials for safety concerns. Variations of the CRM include using 
different clinical trial stopping rules, applying dose-escalation restrictions, different number of 
patients per cohort, and different starting dose levels.        
5.1.2 Re-parameterized logit model 
In the original CRM and its variations, single-parameter dose-toxicity response models are 
usually used. For example, in the conventional logit model, β  is the free parameter, and 
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α typically takes a fixed value of 3 . Opinion has diverged about the number of parameters to use 
in the model [16-20]. Supporters for single-parameter models argue that dose-toxicity response 
relationship can be adequately approximated by a single parameter when only focusing in the 
range of the true target dose and that it is not possible to reliably estimate a large number of 
parameters in Phase I clinical trials, which provide only a small amount of information. 
However, as Phase I trials grow in complexity, for example, accounting for late-onset toxicity 
response and combined therapy, single-parameter models face a great challenge to describe the 
underlying outcome model adequately. Furthermore, a recent simulation study performed by 
Gerke and Siedentop [16] showed that the use of a two-parameter model may lead to improved 
design performance compared to the use of a one-parameter model.  
In the dose-toxicity response models for the CRM design, the use of rescaled doses 
obscures the interpretations of parameters, although it may promote a reasonable fit to models 
[7] or ease computation[6]. For example, in the conventional logit model, how are α  and β  
associated with the assumed dose-toxicity response curve? Understanding the interpretations of 
parameters helps to determine the number of free parameters in a model, and set up sensible 
prior distributions that genuinely reflect prior belief. 
In the following, we will describe step by step how we developed the re-parameterized 
logit model which has more interpretable parameters than those in the conventional model, and 
then show some examples of the implications for the prior distribution of the toxicity probability 
at the starting dose level when α in the conventional logit model takes different fixed values and 
prior distributions. 
 60 
Suppose that 0α and 0β  are the prior means for α and  β  respectively (if α is not a free 
parameter, 0α would be the fixed value for α ). According to the definition of rescaled doses, 
substitute jp by jπ , α by 0α , and β  by 0β in Equation (7), we can get: 
 *0 0log( ) exp( )1
j
j
j
z
π
α β
π
= +
−
 (9) 
From Equation (9), we can derive * 0 0exp( )[log( ) ]1
j
j
j
z
πβ α
π
= − −
−
, plug it into Equation (7), we 
get: 
 0 0log( ) exp( )[log( ) ]1 1
j j
j j
p
p
π
α β β α
π
= + − −
− −
 (10) 
Substituting index j  by i in the above equation, we have: 
 0 0log( ) exp( )[log( ) ]1 1
i i
i i
p
p
π
α β β α
π
= + − −
− −
 (11) 
Subtracting (11) from (10), we get: 
 0log( ) log( ) exp( )[log( ) log( )]1 1 1 1
j ji i
j i j i
p p
p p
π πβ β
π π
− = − −
− − − −
 (12) 
log( ) log( )
1 1
j i
j i
p p
p p
−− −  is the log odds ratio of having toxicity response between dose levels j  
and i , and log( ) log( )
1 1
j i
j i
π π
π π
−
− −
is the initially guessed log odds ratio for these two dose 
levels. Since j  and i are arbitrarily chosen from 1,2,..., J , the conventional logit model actually 
assumes that for any pair of dose levels, the ratio of true log odds ratio and the initially guessed 
log odds ratio is the same and positive.  
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Let sp and sπ are the true and initially assumed toxicity probability at the starting dose 
level respectively, plug them into Equation (12), add log( )
1
s
s
p
p−  to the two sides of the equation, 
and substitute 0exp( )β β−  by γ , which is the ratio of true log odds ratio and the initially 
guessed log odds ratio for any pair of dose levels, then we get the re-parameterized logit model: 
 log( ) log( ) [log( ) log( )]
1 1 1 1
j js s
j s j s
p p
p p
π πγ
π π
= + −
− − − −
 (13) 
Arguably sp  and γ  in the re-parameterized model are more interpretable than α  and β . 
Figure 5.1 shows the relationship of sp  and γ to the assumed true dose-toxicity curve. In this 
example, 0.05sπ = , and the starting dose level is the lowest dose level. Red open circles 
correspond to the initially guessed toxicity probabilities; open circles in other colors correspond 
to the assumed true toxicity probabilities when sp and γ take different values. From Equation 
(13), we know that all j jp π=  if s sp π=  and 1γ =  , which implies that the initially guessed 
dose-toxicity curve (red curve) is the same as the assumed true dose-toxicity curve when s sp π=  
and 1γ = . We observe that when we keep 1γ =  and change sp , the assumed true curves have the 
same shape as the initially guessed and the smaller sp , the lower assumed true curve; if we keep 
0.05sp =  and change γ , the assumed true curves will start from the same point as the initially 
guessed but different shapes. We also observe that the smaller γ , the more slowly the assumed 
true curve increases with the increase of dose levels. Therefore, sp  and γ are interpretable with 
respect to their association with the assumed true dose-toxicity curve, which helps to set up prior 
distributions that genuinely reflect investigators’ prior belief.  
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Figure 5.1 The relationship of sp  and γ to the Assumed Dose-toxicity Curve 
 
The transformations between ( sp ,γ ) and (α , β ) are shown in the following two 
equations: 
 
0 0
1
1 exp( [ exp( )[log( ) ]])
1
s
s
s
p
π
α β β α
π
=
+ − + − −
−
 (14) 
 0exp( )γ β β= −  (15) 
Equation (14) shows that the toxicity probability at the starting dose level is a function of α , β , 
prior means and its initial guess, and Equation (15) shows that γ  is only related with β  and its 
prior mean. We find that we can get the priors for sp and γ  from the priors for α  and β  by the 
absolute Jacobian of the transformation, however, it may be difficult or impossible to obtain the 
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priors for α  and  β  from the priors for sp and γ  because we need to know 0α  and 0β  in 
advance but they are related with the priors for α  and  β . 
We will now look at the corresponding prior distributions on sp when α takes different 
fixed values and different prior distributions described in Table 5.1. We assume the prior 
distribution of β  is normal with mean 0 and variance 1.34, which is the default prior distribution 
for β in the R package “dfcrm”. We also assume the starting dose level is the lowest dose level, 
and the initial guess for its toxicity probability is 0.05.  
 
 
Table 5.1 Different Choices of Values/Prior Distributions for α  
 
α  
Value/Prior Distribution 
-6 
-3 
0 
3 
6 
Normal with mean 3 and variance 1 
Normal with mean -6 and variance 10 
Normal with mean 3 and variance100 
 
 
 
To obtain the prior density function for sp , we create a set of 10000 random draws from 
the prior distribution for β , and also for α  if α is not a fixed parameter, then calculate sp by 
applying Equation (14) each of the 10000 parameter pairs ( ,i iα β ). For each scenario, we draw 
the prior density plot and the empirical cumulative distribution function (CDF) plot for sp based 
on the simulated data. 
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Figure 5.2 Prior Density Plot of sp when α  is Fixed 
 
 
 
Figure 5.3 Enlarged Prior Density Plot of sp  when α  is Fixed 
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Figure 5.2 and Figure 5.3 display the prior density plot of sp  when α  takes different 
fixed values. The initial guessed log odds of having toxicity response, log( )
1
s
s
π
π−
, is equal to -
2.94, which is very close to -3. When α takes -3, 0log( )1
s
s
π
α
π
−
−
  in the Equation (14) is close to 
0 such that sp depends very little on β , which is the only source of the variation. As we can see 
from the above plots, if we choose -3 for α , the prior density of sp is close to point mass at 0.05, 
which would be only appropriate if, at the beginning of a trial, the investigator is nearly 100% 
sure that the toxicity probability at the starting dose level is 0.05. From the original 
parameterization this is not at all obvious. When α  takes fixed values -6, 3 and 6, we observe 
that the corresponding prior distribution of   sp  is bimodal with a mode near 0 and a mode near 
1. The reason for this is because of Jocobian for transforming the probability from the logit scale 
to the original scale. Although the left-hand mode is higher than the right-hand mode, this 
bimodality raises the worry whether a design would behave unexpectedly if the first few accruals 
experience toxicity responses, to be discussed in Section 5.1.3. 
Figure 5.4 displays the empirical cumulative distribution (ECDF) of sp calculated from 
the simulated data. The ECDF curve is very steep when 3α = − , and the other curves except for 
the one when 0α =  show that we initially assume there are more than 20% chances that the 
toxicity probability at the starting dose level  is larger than 0.6. In Phase I clinical trials, it would 
seem likely that investigators would usually be uncomfortable agreeing with this belief.  
Therefore, assuming fixed values of 6− , 3 and 6 for α seems not quite realistic under our setting 
for sπ and prior distribution of β . 
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Figure 5.4 ECDF Plot of sp when α is Fixed 
 
 
 
Figure 5.5 Prior Density Plot of sp  when α is Free 
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Figure 5.5 displays the prior density plot of sp when   α  follows normal distribution with 
mean 3 and different variances. All the corresponding prior distributions for sp  are bimodal at 
two ends. An interesting finding is that as the variance increases, the left-hand mode lowers, 
while the right-hand mode rises. 
 
 
Figure 5.6 ECDF Plot of sp  when α is Free 
 
Figure 5.6 displays the empirical cumulative distribution of sp calculated from the 
simulated data when α  is free. For each of these priors, the chance exceeds 20% that the toxicity 
risk at the starting dose level is larger than 0.6. For the same reason illustrated in the previous 
paragraph, the prior distributions for sp induced from those prior distributions for α  are not 
sensible in most of Phase I clinical trials. 
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In summary, the lessons we conclude from the above investigation are: 
• The choices of fixed value or prior distributions for α  in the conventional logit model are 
not arbitrary. We should consider carefully about their implications for the prior 
distribution for sp . The typical fixed value of 3 that α takes may not be reasonable under 
some settings. 
• We recommend using the re-parameterized logit model with interpretable parameters, 
which can facilitate the elicitation of sensible priors that genuinely reflect investigators’ 
prior belief.  
5.1.3 Choices of prior distribution for sp  
In this section, we will investigate how different choices of prior distribution for sp  affect CRM 
design with respect to the dose assignments for the first five patients, the average number of 
toxicity responses, the average proportion of toxicity responses, the average percentage of 
patients treated at the true target dose level, proportion of simulations where the true target dose 
level is estimated correctly and the proportion of early stopping.   
5.1.3.1 Experiment set-up 
Designs: 
All the testing CRM designs share the following common design parameters: 
• Number of testing dose levels: 5 
• The starting dose level is the first dose level 
• Single-stage 
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• One patient per cohort 
• Maximum sample size: 30 
• Target toxicity rate: 0.25 
• Early Stopping: the posterior toxicity probability at the first dose level is larger than 
(0.1+target)=0.35 
• γ : fixed at 1  
• Initial toxicity probability guesses:  
 logit( ) 3.86 0.92jp j= − +  (16) 
, where logit( ) log( )
1
j
j
j
p
p
p
=
−
, and j  refers to the dose level j . 
Equation (16)  shows the initially guessed outcome model, and its corresponding dose-
toxicity response curve is shown in Figure 5.7, and Table 5.2 lists the initially guessed 
toxicity probabilities at the testing dose levels. 
 
 
Figure 5.7 Initially Guessed Dose-toxicity Response Curve 
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Table 5.2 Initially Guessed Toxicity Probabilities 
 
 Dose Level  
1  2  3  4  5  
Pr(Toxicity)  0.05  0.12  0.25  0.46  0.68  
 
 
 
Table 5.3 CRM Designs with Different Priors for sp  
 
Design # Prior Dose Escalation Restriction Design Name 
1 sp ~Beta(1.47,10); 1γ =  No “Informative” 
2 sp ~Beta(1.11,3) ; 1γ =  No “Mild” 
3 α =3, β =N(0,1.34) No “Bimodal” 
4 sp ~Uniform(0,1) ; 1γ =  No “Uniform” 
5 sp ~Beta(1.47,10) ; 1γ =  Yes “Informative, restriction” 
6 sp ~Beta(1.11,3) ; 1γ =  Yes “Mild, restriction” 
7 α =3, β =N(0,1.34) Yes “Bimodal, restriction” 
8 sp ~Uniform(0,1) ; 1γ =  Yes “Uniform, restriction” 
 
 
Designs differ only with respect to the priors for sp and the use of dose escalation 
restriction. For comparison, we also include the CRM design when α is 3 and the prior 
for β follows normal distribution with mean 0 and variance 1.34. In our current implementation 
of the platform, dose escalation restriction includes no skipping doses and no dose escalation 
immediately after a toxicity response.  Table 5.3 lists all the testing designs along with their 
distinguishing features and names here. The prior Beta(1.47,10) assumes sp  falls within the 
interval (0,0.1) with the probability of 0.47;  the prior Beta(1.11,3) assumes with the probability 
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of 0.23, the induced prior from α =3 and β =N(0,1.34) assumes with the probability of 0.54, and 
the prior uniform (0,1) assumes with the probability of 0.1. The prior density plots for sp are 
drawn in Figure 5.8.  
 
 
 
 
Figure 5.8 Prior Density Plots of sp  
 
Table 5.4 Toxicity Probabilities from the Dose-toxicity Curves with γ =1 
 
 Tier Dose 
1 2 3 4 5 
Model # 
(Name) 
1 
(“Guess=Truth”) 0.05 0.12 0.25 0.46 0.68 
2 
(“Guess<Truth”) 0.25 0.46 0.68 0.84 0.93 
3 
(“Guess>Truth”) 0.0082 0.02 0.049 0.12 0.25 
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Population Model: None, which assumes no baseline characteristics affect either the decision-
making in the designs or patients’ outcomes. 
Outcome Models: 
We consider three underlying outcome models which correspond to the dose-toxicity curves with 
the same shape as the initially guessed (γ =1), as shown in Figure 5.9. The outcome model 
corresponding to the red curve assumes all j jpπ =  and we denote it as “Guess=Truth”; the 
outcome model corresponding to the black solid curve assumes all j jpπ <  and we denote it as 
“Guess<Truth”; the outcome model corresponding to the black dashed curve assumes all 
j jpπ >  and we denote it as “Guess>Truth”. The underlying toxicity probabilities at the testing 
dose levels are listed in Table 5.4. The true target dose level is 3 in the model “Guess=Truth”, 1 
in the model “Guess<Truth”, and 3 in the model “Guess>Truth”. 
 
 
 
Figure 5.9 Underlying Dose-toxicity Curves with γ =1 
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Evaluation Criteria: 
• Average number of toxicity responses 
• Average proportion of toxicity responses 
• Average percentage of patients treated at the true target dose level 
• Proportion of simulations where the true target dose level is estimated correctly 
• Proportion of early stopping 
Number of Replications: 500 
This experiment includes 8 3 24× = scenarios for simulation. 
5.1.3.2 Results 
The accumulating data at the beginning of a clinical trial are very sparse, thus the early decisions 
in a CRM design are strongly influenced by the assumed prior distributions. For this reason, 
appropriate choice of prior distributions is very important to ensure ethical and efficient early 
decision makings. Next, we look at how different priors for sp affect the dose assignments for the 
first five patients. 
 Figure 5.10 - Figure 5.13 display the dose assignments for the first five patients in the 
four testing designs without the dose escalation restriction respectively. Each arrow is away from 
assigned dose level for the previous patient, and points to the assigned dose level for the 
following patient. Blue arrows indicate previous patients do not have toxicity response after 
receiving the assigned dose, and red arrows indicate previous patients have toxicity response. 
The number in each rectangular box is the assigned dose level. For example, in the “informative” 
design, the first patient is assigned the first dose level, if he/she does not have a toxicity 
 74 
response, the next patient will be assigned the second dose level, otherwise, the next patient will 
be assigned the first dose level.  
 
 
 
Figure 5.10 Dose Assignments for the First Five Patients in the “Informative” Design 
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Figure 5.11 Dose Assignments for the First Five Patients in the “Mild” Design 
 
 
 
 
Figure 5.12 Dose Assignments for the First Five Patients in the “Bimodal” Design 
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Figure 5.13 Dose Assignments of the First Five Patients in the “Uniform” Design 
 
From the above four figures, we observe that in the “informative” design no early 
stopping occurs even if the first four enrolled patients all have toxicities. In the other three 
designs, clinical trials are stopped early when even one toxicity response is seen at low doses. 
Compared to the “informative” design, the “mild” design is more conservative, and it generally 
either assigns a lower dose level to the next patient or stops trials given the same accumulating 
data. The “Bimodal” design is the most aggressive when data are sparse, and it assigns the 
highest dose level to the second patient when the first patient does not have a toxicity response, 
which is probably because the mode of the posterior distribution quickly shifts to the lower end 
after observing an non-toxicity response.  We think this might be the reason why the CRM has 
been criticized for being too aggressive in dose escalation and has been recommended to be used 
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with overdose control  [41]. The “uniform” design is the most conservative with very slow 
escalation.   
In general, incorporating the dose escalation restriction into a design makes dose 
assignment more conservative. For the first five patients’ dose assignments, this effect is only 
seen in the “Bimodal” design where skipping dose levels occur. Figure 5.14 shows the dose 
assignments for the first five patients in the “Bimodal, restriction” design. 
 
 
 
Figure 5.14 Dose Assignments for the First Five Patients in the “Bimodal, restriction” Design 
 
 
 
Furthermore, if we know the underlying toxicity probabilities at each dose level, we can 
easily calculate the probability of the n th ( 5n≤ ) patient being assigned a certain dose level 
from the multiplication of the probabilities before this patient. For example, the probability of the 
third patient being assigned the 3rd dose level in the “Informative” design with the underlying 
“Guess=Truth” outcome model would be: 0.95 0.88 0.88 0.74× × = . 
We will look at the evaluation results based on different specified criteria. 
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• Average number of toxicity responses 
 
Table 5.5 Number of Toxicity Responses when “Guess=Truth” 
 
  Number of Toxicity Responses 
Design 
 Mean Standard Error 
“Informative” 6.0 0.063 
“Mild” 5.8 0.077 
“Bimodal” 7.4 0.12 
“Uniform” 4.8 0.092 
“Informative, restriction” 6.1 0.061 
“Mild, restriction” 5.5 0.077 
“Bimodal, restriction” 6.8 0.129 
“Uniform, restriction” 4.9 0.095 
 
 
Table 5.6 Number of Toxicity Responses when “Guess<Truth” 
 
  Number of Toxicity Responses 
Design 
 Mean Standard Error 
“Informative” 9.5 0.073 
“Mild” 5.5 0.15 
“Bimodal” 3.9 0.16 
“Uniform” 3.3 0.14 
“Informative, restriction” 9.5 0.071 
“Mild, restriction” 5.2 0.155 
“Bimodal, restriction” 3.1 0.147 
“Uniform, restriction” 3.3 0.144 
 
 
Table 5.5 - Table 5.7 list the average numbers of toxicity responses and their standard 
errors across different designs and different underlying outcome models.  Designs assuming the 
bimodal prior have the largest standard errors among the designs under the same underlying 
outcome models. The standard errors increase with the increase of the aggressiveness of the 
initial guesses. Incorporating the dose escalation restriction into a design is found not to change 
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the average number of toxicity responses very much. The average number of toxicity responses 
is the largest in the designs assuming the bimodal prior when “Guess=Truth” or “Guess>Truth”, 
and it is the largest in the designs assuming the informative prior when “Guess<Truth”. We 
observe that assuming the uniform prior will decrease the average number of toxicity responses 
in most cases compared to assuming the other priors. 
 
Table 5.7 Number of Toxicity Responses when “Guess>Truth” 
 
  Number of Toxicity Responses 
Design 
 Mean Standard Error 
“Informative” 3.7 0.054 
“Mild” 3.8 0.057 
“Bimodal” 5.9 0.079 
“Uniform” 3.6 0.056 
“Informative, restriction” 3.7 0.053 
“Mild, restriction” 3.9 0.059 
“Bimodal, restriction” 5.3 0.084 
“Uniform, restriction” 3.6 0.055 
 
 
• Average proportion of toxicity responses 
Table 5.8 - Table 5.10 list the average proportions of toxicity responses and their standard 
errors across different designs and different underlying outcome models.  The standard errors 
increase with the increase of the aggressiveness of the initial guesses. Incorporating the dose 
escalation restriction into a design is found not to change the average number of toxicity 
responses very much, except the designs assuming the bimodal prior when “Guess<Truth”. 
Regardless of the underlying outcome models, the designs assuming the informative prior have 
the smallest average proportion of toxicity responses. 
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Table 5.8 Proportion of Toxicity Responses when “Guess=Truth” 
 
  Proportion of Toxicity Responses 
Design 
 Mean Standard Error 
“Informative” 0.201 0.002 
“Mild” 0.229 0.007 
“Bimodal” 0.346 0.008 
“Uniform” 0.252 0.009 
“Informative, restriction” 0.203 0.002 
“Mild, restriction” 0.231 0.008 
“Bimodal, restriction” 0.328 0.008 
“Uniform, restriction” 0.255 0.009 
 
 
Table 5.9 Proportion of Toxicity Responses when “Guess<Truth” 
 
  Proportion of Toxicity Responses 
Design 
 Mean Standard Error 
“Informative” 0.332 0.004 
“Mild” 0.509 0.013 
“Bimodal” 0.665 0.01 
“Uniform” 0.529 0.013 
“Informative, restriction” 0.332 0.004 
“Mild, restriction” 0.535 0.013 
“Bimodal, restriction” 0.576 0.011 
“Uniform, restriction” 0.515 0.013 
 
 
Table 5.10 Proportion of Toxicity Responses when “Guess>Truth” 
 
  Proportion of Toxicity Responses 
Design 
 Mean Standard Error 
“Informative” 0.124 0.002 
“Mild” 0.137 0.004 
“Bimodal” 0.201 0.003 
“Uniform” 0.132 0.004 
“Informative, restriction” 0.123 0.002 
“Mild, restriction” 0.135 0.004 
“Bimodal, restriction” 0.194 0.004 
“Uniform, restriction” 0.129 0.003 
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• Average percentage of patients treated at the true target dose level 
 
Table 5.11 Percentage of Patients Treated when “Guess=Truth” 
 
  Below Target At Target Above Target 
Design 
“Informative” 46.2 47.4 6.4 
“Mild” 50.6 42.4 7.1 
“Bimodal” 31.6 42.7 25.7 
“Uniform” 58.5 35.1 6.4 
“Informative, restriction” 44.0 48.6 7.5 
“Mild, restriction” 52.6 40.3 7.1 
“Bimodal, restriction” 36.5 44.1 19.4 
“Uniform, restriction” 58.7 33.9 7.3 
 
 
Table 5.12 Percentage of Patients Treated when “Guess<Truth” 
 
  Below Target At Target Above Target 
Design 
“Informative” 0 66.6 33.4 
“Mild” 0 78.6 21.4 
“Bimodal” 0 55.8 44.2 
“Uniform” 0 89.4 10.6 
“Informative, restriction” 0 66.5 33.5 
“Mild, restriction” 0 80.4 19.6 
“Bimodal, restriction” 0 62.0 38.0 
“Uniform, restriction” 0 89.5 10.5 
 
 
Table 5.11 - Table 5.13 list the average percentages of patients treated below, at and 
above the true target dose level across different designs and different underlying outcome 
models. The true target dose level is 3 when “Guess=Truth”, 1 when “Guess<Truth”, and 5 when 
“Guess>Truth”. Incorporating the dose escalation restriction into a design is found not to change 
the average percentage of patients very much except for the designs assuming the bimodal prior. 
When “Guess=Truth”, the average percentage of patients treated at the true target dose level is 
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the largest in the designs assuming the informative prior, the “Mild” design and the “Bimodal” 
design have the very similar percentage at the target, however quite different percentages below 
and above the target. The average percentage at the target is the largest in the designs assuming 
the uniform prior when “Guess<Truth” and in the designs assuming the bimodal prior when 
“”Guess>Truth”. 
 
Table 5.13 Percentage of Patients Treated when “Guess>Truth” 
 
  Below Target At Target Above Target 
Design 
“Informative” 72.4 27.6 0 
“Mild” 69.6 30.4 0 
“Bimodal” 30.3 69.7 0 
“Uniform” 69.2 30.8 0 
“Informative, restriction” 76.7 23.3 0 
“Mild, restriction” 68.0 32.0 0 
“Bimodal, restriction” 42.0 58.0 0 
“Uniform, restriction” 70.6 29.4 0 
 
 
• Proportion of simulations where the true target dose level is estimated correctly 
 
Table 5.14 Proportion of Correct Estimation of the True Target when “Guess=Truth” 
 
  Correct Estimation of the True Target 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Informative” 0.616 0.572 0.659 
“Mild” 0.602 0.558 0.645 
“Bimodal” 0.612 0.568 0.655 
“Uniform” 0.508 0.463 0.553 
“Informative, restriction” 0.634 0.59 0.676 
“Mild, restriction” 0.582 0.537 0.626 
“Bimodal, restriction” 0.63 0.586 0.672 
“Uniform, restriction” 0.51 0.465 0.555 
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Table 5.15 Proportion of Correct Estimation of the True Target when “Guess<Truth” 
 
  Correct Estimation of the True Target 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Informative” 0.818 0.781 0.851 
“Mild” 0.448 0.404 0.493 
“Bimodal” 0.14 0.111 0.174 
“Uniform” 0.234 0.198 0.274 
“Informative, restriction” 0.824 0.788 0.856 
“Mild, restriction” 0.418 0.374 0.463 
“Bimodal, restriction” 0.136 0.107 0.169 
“Uniform, restriction” 0.204 0.17 0.242 
 
 
Table 5.16 Proportion of Correct Estimation of the True Target when “Guess>Truth” 
 
  Correct Estimation of the True Target 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Informative” 0.394 0.351 0.438 
“Mild” 0.418 0.374 0.463 
“Bimodal” 0.778 0.739 0.814 
“Uniform” 0.498 0.453 0.543 
“Informative, restriction” 0.352 0.31 0.396 
“Mild, restriction” 0.398 0.355 0.442 
“Bimodal, restriction” 0.724 0.683 0.763 
“Uniform, restriction” 0.478 0.433 0.523 
 
 
Table 5.14 - Table 5.16 list the proportions of correct estimation of the true target and 
their exact 95% confidence intervals across different designs and different underlying outcome 
models. Incorporating the dose escalation restriction into a design is found not to change the 
proportion of correct estimation of the true target very much except that it decreases the 
proportion significantly for the design assuming bimodal prior when “Guess>Truth”. When 
“Guess=Truth”, the design assuming uniform prior has the smallest proportion, while the designs 
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assuming other kinds of priors have similar proportions; when “Guess<Truth”, designs assuming 
informative prior has significant larger proportion than the other designs, while designs assuming 
bimodal priors has the smallest proportion; when “Guess>Truth”, designs assuming bimodal 
prior has the largest proportion, designs assuming uniform prior has the second largest, and 
designs assuming informative and mild priors have similar proportions. 
• Proportion of early stopping 
Table 5.17 - Table 5.19 list the proportions of early stopping and their exact 95% 
confidence intervals across different designs and different underlying outcome models. Under 
the settings in this experiment, since the true target dose level is within the testing dose levels, 
early stopping is not favorable. Incorporating the dose escalation restriction into a design is 
found to increase a little bit the proportion of early stopping except the designs assuming the 
mild or uniform prior when “Guess>Truth”. Regardless of the underlying outcome models, the 
designs assuming the informative prior have the smallest proportion of early stopping. 
 
Table 5.17 Proportion of Early Stopping when “Guess=Truth” 
 
  Early Stopping 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Informative” 0 0 0.006 
“Mild” 0.042 0.026 0.063 
“Bimodal” 0.14 0.111 0.174 
“Uniform” 0.154 0.123 0.189 
“Informative, restriction” 0 0 0.006 
“Mild, restriction” 0.052 0.034 0.075 
“Bimodal, restriction” 0.164 0.133 0.199 
“Uniform, restriction” 0.164 0.133 0.199 
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Table 5.18 Proportion of Early Stopping when “Guess<Truth” 
 
  Early Stopping 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Informative” 0.044 0.028 0.066 
“Mild” 0.492 0.447 0.537 
“Bimodal” 0.814 0.777 0.847 
“Uniform” 0.714 0.672 0.753 
“Informative, restriction” 0.046 0.029 0.068 
“Mild, restriction” 0.526 0.481 0.57 
“Bimodal, restriction” 0.83 0.794 0.862 
“Uniform, restriction” 0.74 0.699 0.778 
 
 
Table 5.19 Proportion of Early Stopping when “Guess>Truth” 
 
  Early Stopping 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Informative” 0 0 0.006 
“Mild” 0.012 0.004 0.026 
“Bimodal” 0.006 0.001 0.017 
“Uniform” 0.016 0.007 0.031 
“Informative, restriction” 0 0 0.006 
“Mild, restriction” 0.006 0.001 0.017 
“Bimodal, restriction” 0.032 0.018 0.051 
“Uniform, restriction” 0.014 0.006 0.029 
 
5.1.3.3 Conclusions 
Results in Section 5.1.3.2 show that no designs perform uniformly best across different criteria 
and different underlying outcome models. A design may perform best according to a certain 
criterion regardless of the underlying outcome models, for example, the designs assuming the 
 86 
informative prior (with and without dose escalation restriction) have the smallest proportion of 
early stopping. Incorporating dose escalation restriction to the designs assuming the informative 
prior, mild prior, or uniform prior is found not to affect the design performance very much. The 
design assuming the bimodal prior, however, benefits significantly from the overdose control 
except for the case when the underlying outcome model is “Guess>Truth” and the evaluation 
criteria are the average percentage of patients treated at the true target dose level and the 
proportion of simulations where the true target dose level is estimated correctly.   
5.1.4 Choices of prior distribution for γ  
In this section, we will investigate how different choices of prior distribution for γ  affect CRM 
design with respect to the dose assignments for the first five patients, the average number of 
toxicity responses, the average proportion of toxicity responses, the average percentage of 
patients treated at the true target dose level, proportion of simulations where the true target dose 
level is estimated correctly and the proportion of early stopping.   
5.1.4.1 Experiment set-up 
Designs: 
All the testing CRM designs share the following common design parameters: 
• Number of testing dose levels: 5 
• The starting dose level is the first dose level 
• Single-stage 
• One patient per cohort 
• Maximum sample size: 30 
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• Target toxicity rate: 0.25 
• Early Stopping: the posterior toxicity probability at the first dose level is larger than 
(0.1+target)=0.35 
• Prior for sp : Beta(1.47,10) 
• Initial toxicity probability guesses: the same as those in the experiment described in 
Section 5.1.3.1. 
• No dose escalation restriction 
Designs differ only with respect to the priors for γ . Figure 5.15 displays the three prior 
distributions under investigation. The prior LogN(0, 0.04) assumes that log( )γ  has normal prior 
with mean 0 and variance 0.04 and that the probability of either 0.5γ ≤ or 2γ ≥  is almost 0, the 
prior LogN(0, 2.89) assumes log( )γ has normal prior with mean 0 and variance 2.89 and that the 
probability of either 0.5γ ≤ or 2γ ≥  is 0.41, and the prior 1 assumes γ is fixed at 1. The priors 
LogN(0,0.04) and LogN(0,2.89) both have their medians at 1. To help remembering different 
designs’ features, we name them according to their priors for γ . Table 5.20 lists the design 
names along with the corresponding prior assumptions.  
 
Table 5.20 CRM Designs with Different Priors for γ  
 
Design # Prior  Design Name 
1 sp ~Beta(1.47,10);γ ~LogN(0,0.04) “Small variance” 
2 sp ~Beta(1.47,10);γ ~LogN(0, 2.89) “Big variance” 
3 sp ~Beta(1.47,10);γ =1 “Fixed” 
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Figure 5.15 Prior Density Plots of γ  
 
Population Model: None, which assumes no baseline characteristics affect either the decision-
making in the designs or patients’ outcomes. 
Outcome Models: 
 
Table 5.21 Toxicity Probabilities from the Dose-toxicity curves with Different γ  
 
 Tier Dose 
1 2 3 4 5 
Model # 
(Name) 
1 
(“ 1γ = ”) 0.05 0.12 0.25 0.46 0.68 
2 
(“ 2γ = ”) 0.05 0.25 0.67 0.93 0.99 
3 
(“ 0.5γ = ”) 0.05 0.08 0.12 0.17 0.25 
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We consider three underlying outcome models. Two of them correspond to the dose-toxicity 
curves with different shapes from the initially guessed, and one is the same as the initially 
guessed.  The curves are shown in Figure 5.16. The underlying toxicity probabilities at the 
testing dose levels are listed in Table 5.21. The true target dose level is 3 in the model “ 1γ = ”, 2 
in the model “ 2γ = ”, and 3 in the model “ 0.5γ = ”. 
 
 
 
Figure 5.16 Underlying Dose-toxicity Curves with Different γ  
 
Evaluation Criteria: 
• Average number of toxicity responses 
• Average proportion of toxicity responses 
• Average percentage of patients treated at the true target dose level 
• Proportion of simulations where the true target dose level is estimated correctly 
• Proportion of early stopping 
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Number of Replications: 500 
This experiment includes 3 3 9× = scenarios for simulation. 
5.1.4.2 Results 
First, we look at how different priors forγ affect the dose assignments for the first five patients. 
 The “Small variance” design and “Fixed” designs have the same dose assignments for 
the first five patients, which is shown in Figure 5.17. Figure 5.18 displays the dose assignments 
for the first five patients in the “Big variance” design. We observe that no early stopping occurs 
before the fifth enrolled patients in these three designs. The “Big variance” design escalates and 
de-escalates dose levels more aggressively than the other two designs.   
 
 
 
Figure 5.17 Dose Assignments for the First Five Patients in the “Small variance” or “Fixed” 
Design 
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Figure 5.18 Dose Assignments for the First Five Patients in the “Big variance” Design 
 
In the next, we will look at the evaluation results based on different specified criteria. 
• Average number of toxicity responses 
 
Table 5.22 Number of Toxicity Responses when “ 1γ = ” 
 
  Number of Toxicity Responses 
Design 
 Mean Standard Error 
“Small variance” 6.2 0.063 
“Big variance” 8.4 0.116 
“Fixed” 6.0 0.063 
 
 
Table 5.22 - Table 5.24 list the average numbers of toxicity responses and their standard 
errors across different designs and different underlying outcome models.  The standard errors 
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increase with the increase of the variance of the prior for γ . The average number of toxicity 
responses is the smallest in the “Fixed” design when “ 1γ = ” or “ 0.5γ = ”, and in the “Big 
variance” design when “ 2γ = ”. Adding a small randomness to the fixed prior seems not to 
improve the design performance with respect to the average number of toxicity responses. 
 
Table 5.23 Number of Toxicity Responses when “ 2γ = ” 
 
  Number of Toxicity Responses 
Design 
 Mean Standard Error 
“Small variance” 7.5 0.063 
“Big variance” 6.8 0.15 
“Fixed” 7.5 0.062 
 
 
 
Table 5.24 Number of Toxicity Responses when “ 0.5γ = ” 
 
  Number of Toxicity Responses 
Design 
 Mean Standard Error 
“Small variance” 4.3 0.062 
“Big variance” 6.2 0.096 
“Fixed” 4.1 0.06 
 
 
 
Table 5.25 - Table 5.27 list the average proportions of toxicity responses and their 
standard errors across different designs and different underlying outcome models.  The standard 
errors are about the same. Regardless of the underlying outcome models, no simulated clinical 
trials have early stopping (to be shown later), and thus the total number of enrolled patients in 
each simulated clinical trial is the same, equal to the maximum sample size. The observed trend 
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with respect to the design performance for the average proportion of toxicity responses is the 
same as those for the average number of toxicity responses. 
 
Table 5.25 Proportion of Toxicity Responses when “ 1γ = ” 
 
  Proportion of Toxicity Responses 
Design 
 Mean Standard Error 
“Small variance” 0.206 0.002 
“Big variance” 0.278 0.004 
“Fixed” 0.201 0.002 
   
 
Table 5.26 Proportion of Toxicity Responses when “ 2γ = ” 
 
  Proportion of Toxicity Responses 
Design 
 Mean Standard Error 
“Small variance” 0.251 0.002 
“Big variance” 0.228 0.005 
“Fixed” 0.25 0.002 
 
 
Table 5.27 Proportion of Toxicity Responses when “ 0.5γ = ” 
 
  Proportion of Toxicity Responses 
Design 
 Mean Standard Error 
“Small variance” 0.145 0.002 
“Big variance” 0.207 0.003 
“Fixed” 0.137 0.002 
 
 
• Average percentage of patients treated at the true target dose level 
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Table 5.28 - Table 5.30 list the average percentages of patients treated below, at and 
above the true target dose level across different designs and different underlying outcome 
models. The true target dose level is 3 when “ 1γ = ”, 2 when “ 2γ = ”, and 5 when 
“ 0.5γ = ”.Adding a small random disturbance to the prior is found not to change the average 
percentage of patients very much except when 0.5γ = . The average propotion of toxicity 
responses is the smallest in the “Fixed” design when “ 1γ = ” or “ 0.5γ = ”, and in the “Big 
variance” design when “ 2γ = ”. 
 
Table 5.28 Percentage of Patients Treated when “ 1γ = ” 
 
  Below Target At Target Above Target 
Design 
“Small variance” 45.1 47.3 7.6 
“Big variance” 30.8 38.7 30.5 
“Fixed” 46.2 47.4 6.4 
   
 
Table 5.29 Percentage of Patients Treated when “ 2γ = ” 
 
  Below Target At Target Above Target 
Design 
“Small variance” 13.7 79.4 6.9 
“Big variance” 38.4 51.2 10.3 
“Fixed” 13.7 79.3 7.1 
  
 
Table 5.30 Percentage of Patients Treated when “ 0.5γ = ” 
 
  Below Target At Target Above Target 
Design 
“Small variance” 84.1 15.9 0 
“Big variance” 29.2 70.8 0 
“Fixed” 89.1 10.9 0 
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• Proportion of simulations where the true target dose level is estimated correctly 
  
Table 5.31 Proportion of Correct Estimation of the True Target when “ 1γ = ” 
 
  Correct Estimation of the True Target 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Small variance” 0.64 0.596 0.682 
“Big variance” 0.572 0.527 0.616 
“Fixed” 0.616 0.572 0.659 
 
 
Table 5.32 Proportion of Correct Estimation of the True Target when “ 2γ = ” 
 
  Correct Estimation of the True Target 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Small variance” 0.926 0.899 0.947 
“Big variance” 0.6 0.556 0.643 
“Fixed” 0.916 0.888 0.939 
 
 
Table 5.33 Proportion of Correct Estimation of the True Target when “ 0.5γ = ” 
 
  Correct Estimation of the True Target 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Small variance” 0.308 0.268 0.351 
“Big variance” 0.844 0.809 0.875 
“Fixed” 0.166 0.134 0.202 
 
 
Table 5.31 - Table 5.33 list the proportions of correct estimation of the true target and 
their exact 95% confidence intervals across different designs and different underlying outcome 
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models. When “ 1γ = ”and “ 2γ = ”, the “Big variance” design has smallest proportion, while the 
other two designs have similar proportions; when “ 0.5γ = ”, the larger the variance of prior for 
γ , the larger proportion the corresponding design has. 
• Proportion of early stopping 
Table 5.34 - Table 5.36 list the proportions of early stopping and their exact 95% 
confidence intervals across different designs and different underlying outcome models. Under 
the settings in this experiment, since the true target dose level is within the testing dose levels, 
early stopping is not favorable. The average proportions of early stopping are all zero, which is 
probably because we use an informative prior with mode of 0.05 for sp . 
 
Table 5.34 Proportion of Early Stopping when “ 1γ = ” 
 
  Early Stopping 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Small variance” 0 0 0.006 
“Big variance” 0 0 0.006 
“Fixed” 0 0 0.006 
  
 
Table 5.35 Proportion of Early Stopping when “ 2γ = ” 
 
  Early Stopping 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Small variance” 0 0 0.006 
“Big variance” 0 0 0.006 
“Fixed” 0 0 0.006 
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Table 5.36 Proportion of Early Stopping when “ 0.5γ = ” 
 
 
  Early Stopping 
Design 
 Proportion 95% CI  Lower Bound Upper Bound 
“Small variance” 0 0 0.006 
“Big variance” 0 0 0.006 
“Fixed” 0 0 0.006 
 
Results in Section 5.1.4.2 show that no designs perform uniformly best across different 
criteria and different underlying outcome models. Adding a small randomness to the fixed prior 
seems not to improve the design performance.  All simulated clinical trials using different 
designs do not have early stoppings. The “Big variance” design has the smallest number and 
average proportion of toxicity responses when 2γ = , and significantly larger average percentage 
of patients treated at the true target dose level and proportion of the correct estimation of the true 
target dose level than the other two designs when 0.5γ = . 
5.2 PATIENT HETEROGENEITY 
Patients enrolled in Phase I cancer trials vary greatly in their current disease status, numbers and 
types of previous treatment, age, sex, genetic profile and many other factors that may impact 
their tolerance to the testing treatment. An example is capecitabine, a widely used 
fluoropyrimidine that requires dose reduction for elderly patients and those with mild to 
moderate renal insufficiency [83]. Ignoring patient heterogeneity in the Phase I trials may do 
harm to patients or recommend an either suboptimal or too toxic dose for future studies. In 
practice, however, probably due to the time and cost constraints, few Phase I clinical trials 
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account for the patient heterogeneity. We think a quantitative demonstration for the potential 
adverse effect that ignoring patient heterogeneity in a particular Phase I trial would help 
investigators to think about risks and benefits more clearly and make a good decision.  
In this section, we will present two hypothetical examples showing how to assess via 
simulation the difference in the expected total personal utility and societal utility between trials 
accounting for patient heterogeneity and trials ignoring patient heterogeneity. One example 
considers a CRM design, and the other considers the standard “3+3” design. In both examples, 
we assume that there are two types of patient populations with respect to their toxicity tolerance 
to the testing drug; the population with better tolerance on average is called “Low Risk”, and the 
other population is called “High Risk”. We also assume that “Low Risk” and “High Risk” 
patients are mixed in 1:1 in a Phase I trial unless they are separated through measurements and 
treated differently in studies.  Suppose patients have underlying dose thresholds for both efficacy 
and toxicity responses, Eθ  and Tθ .  The natural logarithm of dose thresholds follows a bivariate 
normal distribution. Expressions (17) - (18) give the dose thresholds’ distributions for “Low 
Risk”, and “High Risk” patient population respectively. The “L” subscript refers to “Low Risk”, 
and “H” refers to “High Risk”. Figure 5.19 displays the contour plot for their dose thresholds 
distributions.  
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Figure 5.19 Contour Plot for Dose Thresholds Distribution 
The dose thresholds distribution in the mixture patient population can be expressed by Equation 
(19), and the subscript “M” standards for “Mixture”.  
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  The outcome model used in the two examples can be described in Equation (20): 
 
1             
,     { , };  { , };
0            z 
hk
hk
hk
z
y h E T k L H z
θ
θ
<⎧
= ∈ ∈ ∈⎨
>⎩
Z  (20) 
, where hky is the binary response for either efficacy or toxicity. The dose-toxicity and dose-
efficacy curves for different patient populations are drawn in 
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Figure 5.20 Dose-Toxcity Curve 
 
 
 
Figure 5.21 Dose-Efficacy Curve 
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We use the additive utility function to measure the utilities associated with four possible 
outcomes: TE, Te, tE, and te (even though the CRM and standard “3+3” designs only measure 
univariate toxicity outcomes, we can simulate the efficacy responses from the assumed true 
population and outcome models). To measure the expected societal utility, we consider the utility 
function described in Section 3.2.2. Suppose the current standard treatment 
has ( , ) (0.15,0.1)E TP P = , and investigators think if the testing drug at the chosen RP2D has 
( , ) (0.05,0)E TP P = , the societal utility gained from this trial is 0. We also assume the societal 
utility is 0 if no RP2D is chosen at the end of a trial. 
 
Table 5.37 Schemes in Consideration 
 
Scheme # Scheme Name Tier Doses 
1 “Mixed, assumed low risk”  3, 6.6, 9, 15, 21.1 
2 “Mixed, assumed high risk” 0.91, 1.82, 3, 4.56, 6.43 
3 “Separate” 
For low risk: 
3, 6.6, 9, 15, 21.1 
For high risk: 
0.91, 1.82, 3, 4.56, 6.43 
  
 
We compare three schemes, the first and second schemes do not distinguish two patient 
groups and have Phase I trials with mixture patient population. In the first scheme, the 
investigators assume the population is low risk and they test tier doses: 
{3,  6.6,  9,  15,  21.1}L =Z ; the investigators in the second scheme assume the population is high 
risk and they test tier doses: {0.91,  1.82,  3,  4.56,  6.43}H =Z ; the third scheme distinguishes two 
patient groups , and run two separate Phase I trials, the tier doses LZ  is used for the trial with 
pure low risk population, and the tier doses  HZ  is used for the trial with pure high risk 
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population. We run 1000 simulations for each scheme. We will look at comparison results with 
respect to expected total personal utility and expected societal utility under the CRM and the 
standard “3+3” design in the following two sections.   
5.2.1 The CRM 
The three schemes using the CRM share the following common design parameters: 
• Number of testing dose levels: 5 
• The starting dose level is the first dose level 
• Single-stage 
• One patient per cohort 
• Target toxicity rate: 0.25 
• Early Stopping: the posterior toxicity probability at the first dose level is larger than 
(0.1+target)=0.35 
• γ : fixed at 1  
• Prior for sp : Beta(1.47,10) 
• Initial toxicity probability guesses: 0.05, 0.12, 0.25, 0.46, 0.68 
Besides the difference in the testing tier doses, the three schemes use different maximum sample 
size, as illustrated in Table 5.38. 
The evaluation results in Table 5.39 and Table 5.40 show that assuming patients are low 
risk in a trial when the actual patient population is mixed has around eight standard errors larger 
expected total personal utility, and slightly larger expected societal utility than assuming high 
risk patient population. No early stopping is observed in all the simulated trials for the three 
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schemes, thus on average, two separate trials in the third scheme each only enroll half the 
patients of the trial in the first two scheme. Since these two separate trials are run independently 
from each other and they together enroll the same number of patients as the other two trials, it 
would be reasonable to add their expected utilities together and compare with the expected 
utilities in the other two trials. Obviously, trials together in the third scheme have the largest 
expected total personal utility and societal utility.   
 
Table 5.38 Different Maximum Sample Sizes in the CRM 
 
Scheme Name Maximum Sample Size 
“Mixed, assumed low risk” 32 
“Mixed, assumed high risk” 32 
“Separate” Each trial: 16 
 
 
Table 5.39 Expected Total Personal Utility Using the CRM 
 
Scheme Name PEU  Standard Error 
“Mixed, assumed low risk” 6.2 0.088 
“Mixed, assumed high risk” 5.5 0.087 
“Separate” For low risk: 3.3 For high risk: 3.3 
For low risk: 0.058 
For high risk: 0.069 
 
 
Table 5.40 Expected Societal Utility Using the CRM 
 
Scheme Name SEU  Standard Error 
“Mixed, assumed low risk” 0.174 0.001 
“Mixed, assumed high risk” 0.172 0.001 
“Separate” For low risk: 0.22 For high risk: 0.229 
For low risk: 0.001 
For high risk: 0.002 
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5.2.2 The standard “3+3” design 
The following two tables summarize the evaluation results for the three schemes when they are 
applied to the standard “3+3” design. Unlike the CRM designs in Section 0, we do not add the 
maximum sample size restriction to the standard “3+3” design. Results show that clinical trials 
that run separately for different patient groups have much larger expected total personal utility 
and societal utility than clinical trials that do not run separately. 
 
Table 5.41 Expected Total Personal Utility Using the “3+3” Design 
 
Scheme Name PEU  Standard Error 
“Mixed, assumed low risk” 2.2 0.063 
“Mixed, assumed high risk” 2.6 0.064 
“Separate” For low risk: 3.4 For high risk: 3.1 
For low risk: 0.07 
For high risk: 0.078 
  
 
 
Table 5.42 Expected Societal Utility Using the “3+3” Design 
 
Scheme Name SEU  Standard Error 
“Mixed, assumed low risk” 0.135 0.002 
“Mixed, assumed high risk” 0.114 0.002 
“Separate” For low risk: 0.153 For high risk: 0.187 
For low risk: 0.003 
For high risk: 0.003 
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5.2.3 Conclusions 
We present a way to quantitatively measure the expected total personal utility and societal utility 
from a particular clinical trial through simulations. The two hypothetical examples both 
demonstrate that ignoring patient heterogeneity in the CRM and the standard “3+3” design can 
significantly decrease the expected total personal utility and societal utility. 
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6.0  CONCLUSIONS AND FUTURE WORK 
CT simulation has become an important and useful tool to improve the efficiency and accuracy 
of drug development. This dissertation attempts to improve, in particular, the design evaluation 
process in three directions. 
First, we develop an open-source highly flexible and extendible simulation experiment 
platform for evaluating CT designs. The S4 system of classes and methods is utilized. Using 
object-oriented programming provides extensibility through careful, clear interface specification; 
using R, an open-source widely-used statistical language, makes the application extendible by 
the people who design CTs: biostatisticians. Action queue-based simulation framework mimics a 
real CT setting, and adaptively adds actions to the queue, as needed, guided by current state of 
information. Currently, name matching mechanism is used to check interoperability among the 
objects. 
Second, we propose flexible criteria for evaluating Phase I trial designs by assessing 
through CT simulation the expected total personal utility, societal utility and total utility. The 
expected utility paradigm of Bayesian decision theory is well suited to helping CT designers with 
incorporating prior information, and providing a comprehensive design evaluation. 
Third, we present several examples using the platform to investigate important questions 
in clinical trial designs. Specifically, we look at the logit model in the continual reassessment 
method (CRM), choices of parameterization and prior distribution for its model parameters. We 
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demonstrate that using easily interpretable parameters would help to choose the number of free 
parameters in a model, and to set up sensible prior distributions that genuinely reflect the 
investigators’ prior beliefs. We also look at the effect of patient heterogeneity on the 
performance of the standard “3+3” design and the CRM. We observe that ignoring patient 
heterogeneity in the CRM and the standard “3+3” design can significantly decrease the expected 
total personal utility and societal utility. 
To facilitate the use of platform, we have developed an R package called 
CTDesignExplorer based on the source code as of April 30th, 2010. It is intended to be both 
open-source and open-development. Future work will include setting up requirements for 
contributors, publishing CTDesignExplorer, project registration on R-Forge to facilitate 
collaborative software development, adapting code for parallel processing and building a user-
friendly graphical user interface (GUI). 
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